The genetic architecture of the human cerebral cortex.

Katrina L. Grasby[1*], Neda Jahanshad[2*], Jodie N. Painter[1], Lucía Colodro-Conde[1], Janita Bralten[3,4], Derrek P. Hibar[2,5], Penelope A. Lind[1], Fabrizio Pizzagalli[2], Christopher R.K. Ching[2,6], Mary Agnes B. McMahon[2], Natalia Shatokhina[2], Leo C.P. Zsembik[7], Ingrid Agartz[8,9,10,11], Saud Alhusaini[12,13], Marcio A.A. Almeida[14], Dag Alnæs[8,9], Inge K. Amlien[15], Micael Andersson[16,17], Tyler Ard[18], Nicola J. Armstrong[19], Allison Ashley-Koch[20], Manon Bernard[21], Rachel M. Brouwer[22], Elizabeth E.L. Buimer[22], Robin Bülow[23], Christian Bürger[24], Dara M. Cannon[25], Mallar Chakravarty[26,27], Qiang Chen[28], Joshua W. Cheung[2], Baptiste Couvy-Duchesne[29,30,31], Anders M. Dale[32,33], Shareefa Dalvie[34], Tânia K. de Araujo[35], Greig I. de Zubicaray[36], Sonja M.C. de Zwarte[22], Anouk den Braber[37,38], Nhat Trung Doan[8,9], Katharina Dohm[24], Stefan Ehrlich[39], Hannah-Ruth Engelbrecht[40], Susanne Erk[41], Chun Chieh Fan[42], Iryna O. Fedko[37], Sonya F. Foley[43], Judith M. Ford[44], Masaki Fukunaga[45], Melanie E. Garrett[20], Tian Ge[46,47], Sudheer Giddaluru[48], Aaron L. Goldman[28], Nynke A. Groenewold[34], Dominik Grotegerd[24], Tiril P. Gurholt[8,9,10], Boris A. Gutman[2,49], Narelle K. Hansell[31], Mathew A. Harris[50,51], Marc B. Harrison[2], Courtney C. Haswell[52,53], Michael Hauser[20], Dirk J. Heslenfeld[54], David Hoehn[55], Laurena Holleran[25], Martine Hoogman[3,4], Jouke-Jan Hottenga[37], Masashi Ikeda[56], Deborah Janowitz[57], Iris E. Jansen[58,59], Tianye Jia[60,61,62], Christiane Jockwitz[63,64,65], Ryota Kanai[66,67,68], Sherif Karama[69,70,26], Dalia Kasperaviciute[71], Tobias Kaufmann[8,9], Sinead Kelly[72,73], Masataka Kikuchi[74], Marieke Klein[3,4,22], Michael Knapp[75], Annchen R. Knodt[76], Bernd Krämer[77,78], Thomas M. Lancaster[43,79], Phil H. Lee[46,80], Tristram A. Lett[41], Lindsay B. Lewis[81,70], Iscia Lopes-Cendes[35,82], Michelle Luciano[83,84], Fabio Macciardi[85], Andre F. Marquand[86,4], Samuel R. Mathias[87,88], Tracy R. Melzer[89,90,91], Yuri Milaneschi[92], Nazanin Mirza-Schreiber[55], Jose C.V. Moreira[82,93], Thomas W. Mühleisen[63,94,95], Bertram Müller-Myhsok[55,96,97], Pablo Najt[25], Soichiro Nakahara[85,98], Kwangsik Nho[99], Loes M. Olde Loohuis[100], Dimitri Papadopoulos Orfanos[101], John F. Pearson[102,103], Toni L. Pitcher[89,90,91], Benno Pütz[55], Anjanibhargavi Ragothaman[2], Faisal M. Rashid[2], Ronny Redlich[24], Céline S. Reinbold[94,104], Jonathan Repple[24], Geneviève Richard[8,9,105,106], Brandalyn C. Riedel[2,99], Shannon L. Risacher[99], Cristiane S. Rocha[35,82], Nina Roth Mota[3,107,4], Lauren Salminen[2], Arvin Saremi[2], Andrew J. Saykin[99,108], Fenja Schlag[109], Lianne Schmaal[110,111,112], Peter R. Schofield[113,114], Rodrigo Secolin[35,82], Chin Yang Shapland[109], Li Shen[115], Jean Shin[21,116], Elena Shumskaya[3,117,4], Ida E. Sønderby[8,9], Emma Sprooten[4], Lachlan T. Strike[31], Katherine E. Tansey[79], Alexander Teumer[118], Anbupalam Thalamuthu[119], Sophia I. Thomopoulos[2], Diana Tordesillas-Gutiérrez[120,121], Jessica A. Turner[122,123], Anne Uhlmann[34,124], Costanza Ludovica Vallerga[29], Dennis van der Meer[8,9], Marjolein M.J. van Donkelaar[3,4], Liza van Eijk[125,31], Theo G.M. van Erp[85], Neeltje E.M. van Haren[22,126], Daan van Rooij[86,4], Marie-José van Tol[127], Jan H. Veldink[128], Ellen Verhoef[109], Esther Walton[122,129], Yunpeng Wang[8,9], Joanna M. Wardlaw[50,84,130], Wei Wen[119], Lars T. Westlye[8,9,105], Christopher D. Whelan[2,12], Stephanie H. Witt[131], Katharina Wittfeld[132,57], Christiane Wolf[133], Thomas Wolfers[3], Clarissa L. Yasuda[134,82], Dario Zaremba[24], Zuo Zhang[135], Alyssa H. Zhu[2], Marcel P. Zwiers[86,117,4], Eric Artiges[136], Amelia A. Assareh[119], Rosa Ayesa-Arriola[137,121], Aysenil Belger[52], Christine L. Brandt[8,9], Gregory G. Brown[138], Sven Cichon[94,63,104], Joanne E. Curran[14], Gareth E. Davies[139], Franziska Degenhardt[140], Bruno Dietsche[141], Srdjan Djurovic[142,48], Colin P. Doherty[143,144,145], Ryan Espiritu[146], Daniel Garijo[146], Yolanda Gil[146], Penny A. Gowland[147], Robert C. Green[148,149,150], Alexander N. Häusler[151,152], Walter Heindel[153], Beng-Choon Ho[154], Wolfgang U. Hoffmann[118,132], Florian Holsboer[155,55], Georg Homuth[156], Norbert Hosten[157], Clifford R. Jack Jr.[158], MiHyun Jang[146], Andreas Jansen[141,159], Knut Kolskår[8,9,105,106], Sanne Koops[22], Axel Krug[141], Kelvin O. Lim[160], Jurjen J. Luykx[161,22,162], Daniel H. Mathalon[163,164], Karen A. Mather[119,113], Venkata S. Mattay[28,165,166], Sarah Matthews[129], Jaqueline Mayoral Van Son[137,121], Sarah C. McEwen[167,168,169], Ingrid Melle[8,9], Derek W. Morris[25], Bryon A. Mueller[160], Matthias Nauck[170,171], Jan E. Nordvik[106], Markus M. Nöthen[140], Daniel S. O'Leary[154], Nils Opel[24], Marie - Laure Paillère Martinot[136,172], G. Bruce Pike[173], Adrian Preda[174], Erin B. Quinlan[135], Varun Ratnakar[146], Simone Reppermund[119,175], Vidar M. Steen[48,176], Fábio R. Torres[35,82], Dick J. Veltman[92], James T. Voyvodic[52], Robert Whelan[177], Tonya White[126,178], Hidenaga Yamamori[179], Hieab H.H. Adams[180,181], Joshua C. Bis[182], Stephanie Debette[183,184], Charles Decarli[185], Myriam Fornage[186], Vilmundur Gudnason[187,188], Edith Hofer[189,190], M. Arfan Ikram[180], Lenore Launer[191], W. T. Longstreth[192], Oscar L. Lopez[180,193], Bernard Mazoyer[194], Thomas H. Mosley[195], Gennady V. Roshchupkin[180,193,181], Claudia L. Satizabal[196,197,198], Reinhold Schmidt[199], Sudha Seshadri[196,198,,200], Qiong Yang[201], The Alzheimer's Disease Neuroimaging Initiative#, CHARGE consortium#, EPIGEN consortium#, IMAGEN consortium#, SYS consortium#, The Parkinson's Progression Markers Initiative#, Marina K.M. Alvim[134,82], David Ames[202,203], Tim J. Anderson[89,90,91,204], Ole A. Andreassen[8,9], Alejandro Arias-Vasquez[107,3,4], Mark E. Bastin[50,84], Bernhard T. Baune[205], John Blangero[14], Dorret I. Boomsma[37], Henry Brodaty[119,206], Han G. Brunner[3,4,207], Randy L. Buckner[208,209,210], Jan K. Buitelaar[86,4,211], Juan R. Bustillo[212], Wiepke Cahn[213], Vince Calhoun[214,123], Xavier Caseras[79], Svenja Caspers[215,63,65], Gianpiero L. Cavalleri[216,217], Fernando Cendes[134,82], Benedicto Crespo-Facorro[137,121], John C. Dalrymple-Alford[218,90,91], Udo Dannlowski[24], Eco J.C. de Geus[37], Ian J. Deary[84,83], Chantal Depondt[219], Sylvane Desrivières[135,62], Gary Donohoe[25], Thomas Espeseth[105,8], Guillén Fernández[86,4], Simon E. Fisher[109,4], Herta Flor[220], Andreas J. Forstner[140,221,94,104], Clyde Francks[109,4], Barbara Franke[3,107,4], David C. Glahn[87,88], Randy L. Gollub[209,210,80], Hans J. Grabe[132,57], Oliver Gruber[77], Asta K. Håberg[222,223], Ahmad R. Hariri[76], Catharina A. Hartman[224], Ryota Hashimoto[225,179,226], Andreas Heinz[227], Manon H.J. Hillegers[126,228], Pieter J. Hoekstra[224], Avram J. Holmes[229,209], L. Elliot Hong[230], William D. Hopkins[231,232], Hilleke E. Hulshoff Pol[22], Terry L. Jernigan[233,42,138,33], Erik G. Jönsson[11,9], René S. Kahn[234,22], Martin A. Kennedy[103], Tilo T.J.

Kircher[141], Peter Kochunov[230], John B.J. Kwok[235,114,113], Stephanie Le Hellard[48,176], Nicholas G. Martin[30], Jean-Luc Martinot[136], Colm McDonald[25], Katie L. McMahon[236], Andreas Meyer-Lindenberg[237], Rajendra A. Morey[52,53], Lars Nyberg[16,17,238], Jaap Oosterlaan[239,240,241], Roel A.. Ophoff[100], Tomas Paus[242,243,244], Zdenka Pausova[21,245], Brenda W.J.H. Penninx[92], Tinca J.C. Polderman[58], Danielle Posthuma[58,246], Marcella Rietschel[131], Joshua L. Roffman[209], Laura M. Rowland[230], Perminder S. Sachdev[119,247], Philipp G. Sämann[55], Gunter Schumann[135,62], Kang Sim[248], Sanjay M. Sisodiya[71,249], Jordan W. Smoller[46,209,250], Iris E. Sommer[251,228,127,224], Beate St Pourcain[129,109,4], Dan J. Stein[34,252], Arthur W. Toga[18], Julian N. Trollor[175,119], Nic J.A. Van der Wee[253], Dennis van 't Ent[37], Henry Völzke[118], Henrik Walter[41], Bernd Weber[152,151], Daniel R. Weinberger[28,254], Margaret J. Wright[31,255], Juan Zhou[256], Jason L. Stein[7**], Paul M. Thompson[2**], Sarah E. Medland[1**]

1 *Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.*
2 *Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, USA.*
3 *Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands.*
4 *Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.*
5 *Neuroscience Biomarkers, Janssen Research and Development, LLC, San Diego, USA.*
6 *Graduate Interdepartmental Program in Neuroscience, University of California Los Angeles, Los Angeles, USA.*
7 *Department of Genetics & UNC Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, USA.*
8 *NORMENT - K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.*
9 *NORMENT - K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.*
10 *Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.*
11 *Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.*
12 *Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.*
13 *Neurology Department, University of California at San Francisco, San Francisco, USA.*
14 *Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Brownsville, USA.*
15 *Centre for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Oslo, Norway.*
16 *Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.*
17 *Umeå Center for Functional Brain Imaging, Umeå University, Umeå, Sweden.*
18 *Laboratory of Neuro Imaging, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California, Los Angeles, USA.*
19 *Mathematics and Statistics, Murdoch University, Murdoch, Australia.*
20 *Duke Molecular Physiology Institute, Duke University Medical Center, Durham, USA.*
21 *The Hospital for Sick Children, University of Toronto, Toronto, Canada.*
22 *Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.*
23 *Institute for Radiology and Neuroradiology, University Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany.*
24 *Department of Psychiatry, University of Münster, Münster, Germany.*
25 *Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway , Galway, Ireland.*
26 *Douglas Mental Health University Institute, McGill University, Montreal, Canada.*
27 *Departments of Psychiatry and Biological and Biomedical Engineering, McGill University, Montreal, Canada.*
28 *Lieber Institute for Brain Development, Baltimore, USA.*
29 *Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.*
30 *Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.*
31 *Queensland Brain Institute, University of Queensland, St Lucia, Australia.*
32 *Department of Neurosciences, University of California, San Diego, La Jolla, USA.*
33 *Department of Radiology, University of California San Diego, San Diego, USA.*
34 *Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.*
35 *Department of Medical Genetics, School of Medical Sciences, University of Campinas - UNICAMP, Campinas, Brazil.*
36 *Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.*
37 *Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
38 *Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.*
39 *Division of Psychological & Social Medicine and Developmental Neurosciences, Technische Universität Dresden, Dresden, Germany.*
40 *Division of Human Genetics, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.*
41 *Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.*
42 *Department of Cognitive Science, University of California San Diego, San Diego, USA.*
43 *Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, UK.*
44 *San Francisco Veterans Administration Medical Center, San Francisco, USA.*
45 *Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan.*
46 *Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA.*
47 *Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, USA.*
48 *NORMENT - K.G. Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Norway.*
49 *Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, USA.*
50 *Centre for Clinical Brain Sciences and Edinburgh Imaging, University of Edinburgh, Edinburgh, UK.*
51 *Division of Psychiatry, University of Edinburgh, Edinburgh, UK.*
52 *Duke UNC Brain Imaging and Analysis Center, Duke University Medical Center, Durham, USA.*
53 *Mental Illness Research Education and Clinical Center for Post Deployment Mental Health, Durham VA Medical Center, Durham, USA.*

54 *Department of Cognitive and Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
55 *Max Planck Institute of Psychiatry, Munich, Germany.*
56 *Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.*
57 *Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.*
58 *Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
59 *Department of Neurology, Alzheimer Center, Amsterdam Neuroscience, Vrije Universiteit Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
60 *Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.*
61 *Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry of Education, Shanghai, China.*
62 *Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.*
63 *Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany.*
64 *Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany.*
65 *JARA-BRAIN, Jülich-Aachen Research Alliance, Jülich, Germany.*
66 *Department of Neuroinformatics, Araya, Inc., Tokyo, Japan.*
67 *Sackler Centre for Consciousness Science, School of Psychology, University of Sussex, Falmer, UK.*
68 *Earth-Life Science Institute, Tokyo Institute of Technology, Tokyo, Japan.*
69 *Department of Psychiatry, McGill University, Montreal, Canada.*
70 *McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada.*
71 *Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.*
72 *Public Psychiatry Division, Massachusetts Mental Health Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.*
73 *Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.*
74 *Department of Genome Informatics, Graduate School of Medicine, Osaka University, Suita, Japan.*
75 *Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany.*
76 *Department of Psychology and Neuroscience, Duke University, Durham, USA.*
77 *Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany.*
78 *Centre for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry & Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.*
79 *MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.*
80 *Department of Psychiatry, Harvard Medical School, Boston, USA.*
81 *McGill Centre for Integrative Neuroscience, McGill University, Montreal, Canada.*
82 *BRAINN - Brazilian Institute of Neuroscience and Neurotechnology, Campinas, Brazil.*
83 *Department of Psychology, University of Edinburgh, Edinburgh, UK.*
84 *Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.*
85 *Department of Psychiatry and Human Behavior, School of Medicine University of California, Irvine, Irvine, USA.*
86 *Department of Cognitive Neuroscience, Radboud university medical center, Nijmegen, The Netherlands.*
87 *Department of Psychiatry, Yale University School of Medicine, New Haven, USA.*
88 *Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, USA.*
89 *Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.*
90 *New Zealand Brain Research Institute, Christchurch, New Zealand.*
91 *Brain Research New Zealand - Rangahau Roro Aotearoa, Christchurch, New Zealand.*
92 *Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience and GGZinGeest, Amsterdam, The Netherlands.*
93 *IC - Institute of Computing, Campinas, Brazil.*
94 *Department of Biomedicine, University of Basel, Basel, Switzerland.*
95 *Cécile and Oskar Vogt Institute of Brain Research, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.*
96 *Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.*
97 *Institute of Translational Medicine, Liverpool, United Kingdom.*
98 *Drug Discovery Research, Astellas Pharmaceuticals, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.*
99 *Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, USA.*
100 *Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, USA.*
101 *NeuroSpin, CEA, Université Paris-Saclay, Gif-sur-Yvette, France.*
102 *Biostatistics and Computational Biology Unit, University of Otago. Christchurch, Christchurch, New Zealand.*
103 *Department of Pathology and Biomedical Science, University of Otago, Christchurch, Christchurch, New Zealand.*
104 *Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.*
105 *Department of Psychology, University of Oslo, Oslo, Norway.*
106 *Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.*
107 *Department of Psychiatry, Radboud university medical center, Nijmegen, The Netherlands.*
108 *Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.*
109 *Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands.*
110 *Orygen, The National Centre of Excellence for Youth Mental Health, Melbourne, Australia.*
111 *The Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.*
112 *Department of Psychiatry, Vrije Universiteit University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
113 *Neuroscience Research Australia, Sydney, Australia.*
114 *School of Medical Sciences, University of New South Wales, Sydney, Australia.*
115 *Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, USA.*
116 *Population Neuroscience & Developmental Neuroimaging, Bloorview Research Institute, University of Toronto, East York, Canada.*
117 *Donders Centre for Cognitive Neuroimaging, Radboud University, Nijmegen, The Netherlands.*
118 *Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.*
119 *Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.*
120 *Neuroimaging Unit, Technological Facilities, Valdecilla Biomedical Research Institute IDIVAL, Santander, Spain.*
121 *Centro Investigacion Biomedica en Red Salud Mental, Santander, Spain.*

122 *Department of Psychology, Georgia State University, Atlanta, USA.*
123 *Mind Research Network, Albuquerque, USA.*
124 *Department of Psychiatry, University of Vermont, Burlington, USA.*
125 *School of Psychology, University of Queensland, Brisbane, Australia.*
126 *Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.*
127 *Cognitive Neuroscience Center, Department of Neuroscience, University Medical Center Groningen, Groningen, The Netherlands.*
128 *Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.*
129 *MRC Integrative Epidemiology Unit, Department of Population Health Sciences, Bristol Medical School, Bristol, UK.*
130 *UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.*
131 *Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.*
132 *German Center for Neurodegenerative Diseases Rostock/Greifswald, Greifswald, Germany.*
133 *Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany.*
134 *Department of Neurology, FCM, UNICAMP, Campinas, Brazil.*
135 *Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.*
136 *INSERM Unit 1000 - Neuroimaging & Psychiatry, Paris Saclay University,Gif sur Yvette, France.*
137 *Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Santander, Spain.*
138 *Department of Psychiatry, University of California San Diego, San Diego, USA.*
139 *Avera Institute for Human Genetics, Sioux Falls, USA.*
140 *Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.*
141 *Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.*
142 *Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.*
143 *Department of Neurology, St James's Hospital, Dublin, Ireland.*
144 *Academic Unit of Neurology, TBSI, Dublin, Ireland.*
145 *Future Neuro, Royal College of Surgeons in Ireland, Dublin, Ireland.*
146 *Information Sciences Institute, University of Southern California, Los Angeles, USA.*
147 *Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK.*
148 *Brigham and Women's Hospital, Boston, USA.*
149 *The Broad Institute, Boston, USA.*
150 *Harvard Medical School , Boston, USA.*
151 *Center for Economics and Neuroscience, University of Bonn, Bonn, Germany.*
152 *Institute of Experimental Epileptology and Cognition Research, University Hospital Bonn, Germany.*
153 *Department of Clinical Radiology, University of Münster, Münster, Germany.*
154 *Department of Psychiatry, University of Iowa College of Medicine, Iowa City, USA.*
155 *HMNC Holding GmbH, Munich, Germany.*
156 *University Medicine Greifswald, Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, Greifswald, Germany.*
157 *Institute of Diagnostic Radiology and Neuroradiology, Greifswald, Germany.*
158 *Dept of Radiology, Mayo Clinic, Rochester, USA.*
159 *Core-Unit Brainimaging, Faculty of Medicine, University of Marburg, Marburg, Germany.*
160 *Department of Psychiatry, University of Minnesota, Minneapolis, USA.*
161 *Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.*
162 *Department of Psychiatry, ZNA hospitals, Antwerp, Belgium.*
163 *Department of Psychiatry and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, USA.*
164 *Mental Health Service 116d, Veterans Affairs San Francisco Healthcare System, San Francisco, USA.*
165 *Department of Neurology, Johns Hopkins University, Baltimore, USA.*
166 *Department of Radiology, Johns Hopkins University, Baltimore, USA.*
167 *Department of Psychiatry, University of California San Diego, La Jolla, USA.*
168 *Pacific Brain Health Center, Santa Monica, United States.*
169 *John Wayne Cancer Institute, Santa Monica, United States.*
170 *Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.*
171 *German Centre for Cardiovascular Research, Greifswald, Germany.*
172 *Child and adolescent psychiatry department, APHP Pitié Salpêtrière hospital,Paris,France.*
173 *Radiology and Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.*
174 *School of Medicine, University of California Irvine, Irvine, USA.*
175 *Department of Developmental Disability Neuropsychiatry, University of New South Wales, Sydney, Australia.*
176 *Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway.*
177 *School of Psychology, Trinity College Dublin, Dublin, Ireland.*
178 *Department of Radiology, Erasmus University Medical Centre, Rotterdam, The Netherlands.*
179 *Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan.*
180 *Department of Epidemiology, Erasmus MC Medical Center, Rotterdam, The Netherlands.*
181 *Department of Radiology and Nuclear Medicine, Erasmus MC Medical Center, Rotterdam, The Netherlands.*
182 *Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, USA.*
183 *team VINTAGE, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France.*
184 *Department of Neurology, CHU de Bordeaux, Bordeaux, Franc.*
185 *Department of Neurology, University of California, Davis, Sacramento, USA.*
186 *Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, USA.*
187 *Icelandic Heart Association, Kopavogur, Iceland.*
188 *Faculty of Medicine, University of Iceland, Reykjavik, Iceland.*
189 *Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria.*
190 *Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.*
191 *Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, USA.*
192 *Departments of Neurology and Epidemiology, University of Washington, Seattle, USA.*

193 *Medical Informatics, Erasmus MC Medical Center, Rotterdam, The Netherlands.*
194 *Neurodegeneratives Diseases Institute-CNRS UMR 5293, University of Bordeaux, France;.*
195 *MIND Center, University of Mississippi Medical Center, Jackson, USA.*
196 *Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, USA.*
197 *Department of Epidemiology & Biostatistics, University of Texas Health Sciences Center, San Antonio, USA.*
198 *Department of Neurology, Boston University School of Medicine, Boston, USA.*
199 *Departments of Genetics and Neuroscience, Yale University School of Medicine, New Haven, USA.*
200 *Framingham Heart Study and Department of Neurology, Boston University School of Medicine, Boston, USA.*
201 *Department of Biostatistics, Boston University School of Public Health, Boston, USA.*
202 *Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia.*
203 *National Ageing Research Institute, Melbourne, Australia.*
204 *Department of Neurology, Canterbury District Health Board, Christchurch, New Zealand.*
205 *Department of Psychiatry, The University of Melbourne, Melbourne, Australia.*
206 *Dementia Centre for Research Collaboration, University of New South Wales, Sydney, Australia.*
207 *Department of Clinical Genetics and School for Oncology & Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, The Netherlands.*
208 *Department of Psychology and Center for Brain Science, Harvard University, Boston, USA.*
209 *Department of Psychiatry, Massachusetts General Hospital, Boston, USA.*
210 *Department of Radiology, Massachusetts General Hospital , Boston, USA.*
211 *Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands.*
212 *Department of Psychiatry, University of New Mexico, Albuquerque, USA.*
213 *Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.*
214 *Department of Electrical and Computer Engineering, The University of New Mexico, Albuquerque, USA.*
215 *Institute for Anatomy I, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.*
216 *Molecular and Cellular Therapeutics, The Royal College of Surgeons In Ireland, Dublin, Ireland.*
217 *The SFI FutureNeuro Research Centre, Dublin, Ireland.*
218 *Department of Psychology, University of Canterbury, Christchurch, New Zealand.*
219 *Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.*
220 *Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.*
221 *Department of Psychiatry (UPK), University of Basel, Basel, Switzerland.*
222 *Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.*
223 *Department of Radiology and Nuclear medicine, Trondheim, Norway.*
224 *Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.*
225 *Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan.*
226 *Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.*
227 *Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.*
228 *Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.*
229 *Department of Psychology, Yale University, New Haven, USA.*
230 *Maryland Psychiatry Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, USA.*
231 *Neuroscience Institute, Georgia State University, Atlanta, USA.*
232 *Division of Developmental and Cognitive Neuroscience, Yerkes National Primate Research Center, Atlanta, USA.*
233 *Center for Human Development, University of California San Diego, La Jolla, USA.*
234 *Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.*
235 *Neurogenetics and Epigenetics, Brain and Mind Centre, The University of Sydney, Sydney, Australia.*
236 *Herston Imaging Research Facility, School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia.*
237 *Department of Psychiatry and Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.*
238 *Department of Radiation Sciences, Umeå University, Umeå, Sweden.*
239 *Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.*
240 *Department of Pediatrics, Vrije Universiteit Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
241 *Clinical Neuropsychology section, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
242 *Bloorview Research Institute, University of Toronto, Toronto, Canada.*
243 *Departments of Psychology and Psychiatry, University of Toronto, Toronto, Canada.*
244 *Centre for Developing Brain, Child Mind Institute, New York City, USA.*
245 *Department of Physiology, University of Toronto, Toronto, Canada.*
246 *Department of Clinical Genetics, Vrije Universiteit Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.*
247 *Neuropsychiatric Institute, The Prince of Wales Hospital, Sydney, Australia.*
248 *General Psychiatry, Institute of Mental Health, Singapore, Singapore.*
249 *Chalfont Centre for Epilepsy, Chalfont-St-Peter, UK.*
250 *Stanley Center for Psychiatric Research, Broad Institute, Boston, USA.*
251 *Department of Medical and Biological Psychology, University of Bergen, Bergen, Norway.*
252 *MRC Unit on Risk & Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa.*
253 *Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.*
254 *Psychiatry, Neurology, Neuroscience, Genetics, Johns Hopkins University, Baltimore, USA.*
255 *Centre for Advanced Imaging, University of Queensland, Brisbane, Australia.*
256 *Center for Cognitive Neuroscience, Neuroscience and behavioral disorders program, Duke-National University of Singapore Medical School, Singapore, Singapore.*

Authorship contributions (*,**) and authorship lists for the consortium authors (#) appear in the Supplementary Notes.

Summary
The cerebral cortex underlies our complex cognitive capabilities, yet we know little about the specific genetic loci influencing human cortical structure. To identify genetic variants impacting cortical structure, we conducted a genome-wide association meta-analysis of brain MRI data from 35,660 individuals with replication in 15,578 individuals. We analysed the surface area and average thickness of the whole cortex and 34 regions with known functional specialisations. We identified 206 nominally significant loci ($P \leq 5 \times 10^{-8}$); 150 survived multiple testing correction ($P \leq 8.3 \times 10^{-10}$; 140 surface area; 10 thickness). We found significant enrichment for loci influencing total surface area within regulatory elements active during prenatal cortical development, supporting the radial unit hypothesis. Loci impacting regional surface area cluster near genes in Wnt signalling pathways, known to influence progenitor expansion and areal identity. Variation in cortical structure is genetically correlated with cognitive function, Parkinson's disease, insomnia, depression and ADHD.

The human cerebral cortex is the outer grey matter layer of the brain, which is implicated in multiple aspects of higher cognitive function. Its distinct folding pattern is characterised by convex (*gyral*) and concave (*sulcal*) regions. Computational brain mapping approaches use the consistent folding patterns across individual cortices to label brain regions[1] (Fig. 1a). During fetal development excitatory neurons, the predominant neuronal cell-type in the cortex, are generated from neural progenitor cells in the developing germinal zone[2]. The radial unit hypothesis[3] posits that the expansion of cortical surface area (SA) is driven by the proliferation of these neural progenitor cells, whereas thickness (TH) is determined by the number of neurogenic divisions. Variation in global and regional measures of cortical SA and TH are associated with neuropsychiatric disorders and psychological traits[4-6] (Supplementary Table 1). Twin and family-based brain imaging studies show that SA and TH measurements are highly heritable and are largely influenced by independent genetic factors[7,8]. Despite extensive studies of genes impacting cortical structure in model organisms[9], our current understanding of genetic variation impacting human cortical size and patterning is limited to rare, highly penetrant variants[10,11]. These variants often disrupt cortical development, leading to altered post-natal structure. However, little is known about how common genetic variants impact human cortical SA and TH.

To address this, we conducted genome-wide association meta-analyses of cortical SA and TH measures in 51,238 individuals from 58 cohorts from around the world (Supplementary Fig. 1; Supplementary Tables 2–4). Cortical measures were extracted from structural brain MRI scans in regions defined by gyral anatomy using the Desikan-Killiany atlas[12]. Image processing and quality control are described in the Methods. We analysed two global measures, total SA and average TH, and SA and TH for 34 regions averaged across both hemispheres, yielding 70 distinct phenotypes (Fig. 1a; Supplementary Table 1).

Within each cohort genome-wide association (GWAS) for each of the 70 phenotypes was conducted using an additive model (Methods). To identify genetic influences specific to each region, the primary GWAS of regional measures included the global measure of SA or TH as a covariate. To better localise the global findings, regional GWAS were also run without controlling for global measures. To estimate the multiple testing burden associated with analysing 70 phenotypes, we used matrix spectral decomposition[13], which yielded 60 independent traits (Methods). Therefore, we adopted a significance threshold of $P \leq 8.3 \times 10^{-10}$.

A rolling genome-wide meta-analytic approach was used with three phases (Methods; Supplementary Fig. 1). Initial meta-analysis comprised results from 34 ENIGMA cohorts of European ancestry (19,512 participants) and the UK Biobank[14] (10,083 participants of European ancestry; Methods). The second phase included ten additional ENIGMA cohorts of European ancestry (3,121 participants) submitted after the first meta-analysis. Results of this second phase of meta-analysis were used in all follow-up analyses. The third phase included results from eight ENIGMA cohorts of non-European ancestry (2,944 participants). We sought further replication from participants of European ancestry for loci reaching $P \leq 5 \times 10^{-8}$ in four additional ENIGMA cohorts (1,628 participants) and with the CHARGE consortium (as a reciprocal replication; 13,950 participants, excluding UK Biobank). High genetic correlations were observed between the meta-analysed ENIGMA European cohorts (excluding UK Biobank) and the UK Biobank cohort using LD-score regression ($rG_{TotalSA}$ = 1.00, $P = 2.4 \times 10^{-26}$, $rG_{AverageTH}$ = 0.94, $P = 2.5 \times 10^{-19}$) indicating consistent genetic architecture between these 34 ENIGMA cohorts and the single-site, single-scanner UK Biobank cohort.

Across the 70 cortical phenotypes, we identified 213 loci that were nominally genome-wide significant in the second phase of meta-analysis ($P \leq 5 \times 10^{-8}$). Including the non-European cohorts in the meta-analysis yielded an additional 38 loci meeting this threshold, resulting in a total of 251 loci. After including the replication data, 206 loci remained nominally significant (188 influencing SA and 18 influencing TH); 150 of these survived multiple testing ($P \leq 8.3 \times 10^{-10}$; 140 influencing SA and 10 influencing TH; Fig. 1b; Supplementary Table 1; Supplementary Table 5). Significant gene-based association was observed for 479 genes across the 70 cortical phenotypes (Methods; Supplementary Table 6). Figures summarising the meta-analytic results (Manhattan, QQ and Forest plots) are provided in the supplementary materials.



Fig. 1 | Regions of the human cortex and associated genetic loci. a, the 34 cortical regions defined by the Desikan-Killiany atlas[12]; **b**, ideogram of nominal ($P \leq 5 \times 10^{-8}$) and genome-wide significant loci influencing cortical SA and TH; and **c**, number of genome-wide significant ($P \leq 8.3 \times 10^{-10}$) loci influencing cortical SA and TH.

Genetic architecture of total SA and average TH

Common variants explained 33% (SE = 3%) of the variation in total SA and 25% (SE = 2%) in average TH, which approaches a third of the heritability estimated from twin and family studies[8] (Methods; Supplementary Table 1; Supplementary Table 7). We observed a significant negative genetic correlation between total SA and average TH (r_G = -.32, SE = .05, P = 3.9 x 10^{-11}; Fig. 2a), which persisted after excluding the chromosome 17 inversion region known to influence brain size[15-17] (r_G = -.31, SE = .05, P = 4.7 x 10^{-11}). The direction of this correlation suggests that opposing genetic influences may constrain the total cortical size. The small magnitude of this correlation is consistent with the radial unit hypothesis[10] whereby different developmental mechanisms promote SA and TH expansion.

As expected, total SA showed a positive genetic correlation with intracranial volume (ICV); this correlation remained after controlling for height demonstrating that this relationship is not solely driven by body size (Fig. 2a; Supplementary Table 8). The global cortical measures did not show significant genetic correlations with the volumes of major subcortical structures (Fig. 2a), indicating that variation in cortical and subcortical structures are have predominantly independent genetic influences. This is consistent with known differences in cell-type composition between these structures.

To identify if common variation associated with cortical structure perturbs gene regulation during a specific developmental time period or within a given cell-type, we performed partitioned heritability analyses[18] using sets of gene regulatory annotations from adult and fetal brain tissues[19,20]. The strongest enrichment of the heritability for global SA was seen within areas of active gene regulation (promoters and enhancers) in the mid-fetal human brain (Methods; Fig. 2b). We further identified a stronger enrichment in regions of the fetal cortex with more accessible chromatin in the neural progenitor-enriched germinal zone than the neuron-enriched cortical plate[19]. There was also enrichment of active regulatory elements within embryonic stem cells differentiated to neural progenitors[20]. We conducted pathway analyses to determine if there was enrichment of association near genes in known biological pathways (Methods). Among the 241 significant gene-sets there a number were involved in chromatin modification, a process guiding neurodevelopmental fate decisions[21] (Fig. 3c, Supplementary Table 9). These findings suggest that total SA in adults is influenced by common genetic variants that may alter gene regulatory activity in neural progenitor cells during fetal development, supporting the radial unit hypothesis[3]. The strongest evidence of enrichment for average TH was found in active regulatory elements in the adult brain samples, which may reflect processes occurring after mid-fetal development, such as myelination, branching, and pruning[22]. These findings are consistent with the radial unit hypothesis, which proposes that neocortical surface area expansion is largely driven by increases in the neural progenitor pool[3].



Fig. 2 | Genetics of Global Cortical Measures. a, Genetic correlations between global measures and selected morphological traits (β, SE and P values are reported in full in Supplementary Table 8); positive correlations are shown in red, negative correlations are shown in blue; **b**, Partitioned heritability; **c**, Miami plot shows loci associated with global measures (top: surface area, bottom: thickness), green highlights are the loci that reach nominal genome-wide significance in either Phase 2 or Phase 3, the black dashed to black diamonds indicate change in P-value of the lead SNP after replication; **d**, Regional plot for rs1628768; **e**, Effect

of rs1628768 (C allele) on the SA of cortical regions without controlling for global measures; **f**, Regional plot for rs630934; **g**, Effect of rs630934 (A allele) on the TH of cortical regions without controlling for global measures. Within the regional plots the three panels contain: **i)** proxy SNPs and surrounding genes; **ii)** Chromatin state in four RoadMap brain tissues: dorsolateral prefrontal cortex (DPfC), fetal brain (female, Fet-F, and male, Fet-M) and NH-A_astrocytes_primary_cells (NH-A APC). **iii)** BRAINSPAN gene expression in fetal and adult brain tissue (Supplementary Note).

Loci influencing total SA and average TH

Eleven loci were nominally associated with total SA; eight survived correction for multiple testing (Fig. 2c, Supplementary Table 5). While these loci were significantly associated with global measures the effects were not uniform across regions (Fig. 2e; 2g). Five loci influencing total SA have been previously associated with ICV[16] (Fig. 2c). Of these, rs62057153 (P_{phase2} = 2.7 x 10^{-30}; P_{rep} = 6.3 x 10^{-42}), in the highly pleiotropic chromosome 17q21.31 inversion region[15-17] has previously been associated with Parkinson's disease[23], educational attainment[24], and neuroticism[25] (Supplementary Fig. 2a). On 10q24.33, rs1628768 (P_{phase2} = 3.8 x 10^{-13}; P_{rep} = 5.3 x 10^{-18}) is a cortical expression quantitative trait locus (eQTL)[26] for *WBP1L*, *INA,* and the putative schizophrenia genes *AS3MT* and *NT5C2*[27] (CommonMind Consortium [CMC] FDR P = 0.009; Fig. 2d; Supplementary Table 10-11; Methods). This region has been associated with schizophrenia; however, rs1628768 is in low LD with the schizophrenia-associated SNP, rs11191419 (r^2 = 0.15). The 6q21 locus influencing total SA is intronic to *FOXO3* (which also showed a significant gene-based association with total SA, Supplementary Table 6). The minor allele of the lead variant rs2802295 is associated with decreased total SA (P_{phase2} = 2.3 x 10^{-10}; P_{rep} = 9.2 x 10^{-14}) and has previously been associated with lower general cognitive function[28] (rs2490272: $P_{Cognition}$ = 9.9 x 10^{-14}; $r^2_{rs2802295:rs2490272}$ = 1, Supplementary Fig. 2b). The three loci influencing total SA not previously associated with ICV were rs34464850 (P_{phase2} = 1.7 x 10^{-16}; P_{rep} = 2.6 x 10^{-17}) in proximity to genes *TFDP2* and *ATP1B3*, rs11171739 (P_{phase2} = 8.2 x 10^{-9}; P_{rep} = 2.2 x 10^{-10}) located between *RPS26* and *ERBB3*, and rs190958130 (P_{phase2} = 6.2 x 10^{-11}; P_{rep} = 3.3 x 10^{-11}) near *CENPW* (Supplementary Note).

Among the nominally significant results, the 3p24.1 locus (rs12630663; P_{phase2} = 2.0 x 10^{-8}; P_{rep} = 9.7 x 10^{-9}) is of interest due to its proximity (~200kb) to *EOMES* (also known as *TBR2*), which is expressed specifically in intermediate progenitor cells[29], in the developing fetal cortex[2]. rs12630663 is located in a chromosomal region with chromatin accessibility specific to the human fetal cortex germinal zone of human[19]. This region shows significant chromatin interaction with the *EOMES* promoter[29] and contains numerous regulatory elements that when excised via CRISPR/Cas9 in differentiating neural progenitor cells significantly reduced *EOMES* expression[19]. A rare homozygous chromosomal translocation in the region separating the regulatory elements from *EOMES* silences its expression and causes microcephaly[30] (Supplementary Fig. 5).

Four loci were nominally associated with average TH; only one survived correction for multiple testing (Fig. 2c; Supplementary Table 5). The chromosome 3p22.1 locus (rs630934; P_{phase2} = 3.4 x 10^{-10}; P_{rep} = 9.4 x 10^{-12}) is located between *RPSA* (encoding a 40S ribosomal protein with a potential role as a laminin receptor[31]) and *MOBP* (involved in myelination and differentiation of oligodendrocytes[31]). rs630934 is an eQTL for *MOBP* in tibial nerve (P_{GTEx} = 1.17 x 10^{-13}) and for *RPSA* in multiple tissues including cerebellum ($P_{GTEx_cerebellum}$ = 5.4 x 10^{-6}; Fig. 2f; Supplementary Table 10-11). Among the nominally significant results, the 2q11.2 locus (P_{phase2} = 2.1 x 10^{-9}; P_{rep} = 2.1 x 10^{-9}) is of particular interest because rs11692435 is a missense variant (p.A143V) predicted to impact *ACTR1B* function (Supplementary Table 10-11). *ACTR1B* is expressed in numerous tissue types and is a component of the dynactin complex, necessary for vesicle movement along microtubules[32].

Genetic architecture of regional SA and TH

Within individual cortical regions the amount of phenotypic variance explained by common variants was higher for SA (9-31%) than for TH (0.5-16%) (Methods; Fig. 3a-b; Supplementary Table 1; Supplementary Table 7). With few exceptions, the genetic correlations between SA and TH within the same region were moderate and negative (Supplementary Table 12-13), suggesting that genetic variants contributing to the expansion of SA tend to decrease TH. Most genetic correlations between regional surface areas did not survive multiple testing correction, and those that did implied a general pattern of positive correlations between physically adjacent regions and negative correlations with more distal regions (Fig. 3a). This pattern mirrored the phenotypic correlations between regions and was also observed for TH (Fig. 3a-b). The positive genetic correlations were typically between SA of regions surrounding the major, early forming sulci (e.g., pericalcarine, lingual, cuneus, and lateral occipital regions surrounding the calcarine sulcus), which may potentially reflect genetic effects acting on the development of the sulci (see Supplementary Note for further discussion). However, the general pattern of correlations may, in part, depend on the regional partitioning by the Desikan-Killiany atlas[12] (see Supplementary Note for further discussion). Hierarchical clustering of the genetic correlations resulted in a general grouping by physical proximity, with a well-defined cluster in the occipital lobe (Methods; Supplementary Fig. 3).

To further investigate biological pathways influencing areal identity, we summarised the individual regional results using multivariate GWAS analyses[33] separately for SA and TH that modelled the phenotypic correlations between regions (Methods). Pathway analyses of the multivariate SA results showed significant enrichment for 493 gene sets (Fig. 3c-d; Supplementary Table 9), many of which are involved in Wnt signalling, with the canonical Wnt signalling pathway showing the strongest enrichment (P = 3.9 x 10^{-7}). Wnt proteins regulate neural progenitor fate decisions[34,35] and are expressed in spatially specific manners influencing areal identity[9]. Pathway analyses of the multivariate TH results did not yield any findings that survived multiple testing.



Fig. 3 | Genetic and Phenotypic Correlations between cortical regions. a, Surface Area; **b**, Thickness. The regions are referred to by the numbers shown in the legend of **Fig. 1a**. The proportion of variance accounted for by common genetic variants is shown in the first column (h^2_{SNP}). Phenotypic correlations for the UK Biobank are shown in upper triangle while genetic correlations from the second phase of meta-analysis are shown in the lower triangle. All analyses are corrected for the covariates included in the GWAS (Methods). **c**, Enrichment of gene ontology annotations for Total Surface Area; **d**, Enrichment of gene ontology annotations for regional surface area.

Loci influencing regional SA and TH

A total of 177 loci were nominally associated with regional SA and 14 with TH; of these 132 SA and 9 TH loci survived multiple testing correction (Supplementary Table 1; Supplementary Table 5). As shown in Fig. 1b, most loci identified were associated with a single cortical region. Of the loci influencing regional measures, few were associated with global measures, and those that were showed effects in the same direction, implying that the significant regional loci were not due to collider bias[36] (Supplementary Fig. 4).

The strongest regional association was observed on chromosome 15q14 with the precentral SA (rs1080066, P_{phase2} = 6.9 x 10^{-132}; P_{rep} = 4.4 x 10^{-188}; variance explained = 0.87% Fig. 4a-b). Across traits within the 15q14 region we observed 14 independent significant associations from six LD blocks (r2 threshold <=.4; see Fig. 4b, Supplementary Table 1; Supplementary Table 5). As we observed strong association with the SA of both pre- and post-central gyri, we localised the association within the central sulcus in 5,993 unrelated individuals

from the UK Biobank (Methods). The maximal association between rs1080066 and sulcal depth was observed around the *pli de passage fronto-pariétal moyen* (P = 7.9 x 10^{-21}), a region associated with hand fine-motor function in humans[37] and shows distinct depth patterns across different species of primates[38] (see Fig. 4d). Located in a large intergenic region rs1080066 is an eQTL for the downstream gene *THBS1* in whole blood ($P_{BIOS_genelevel}$ = 1.5 x 10^{-9}) with evidence of chromatin interaction between the rs1080066 region and the *THBS1* promoter in neural progenitor cells (Fig. 4a).

Across the 14q23.1 region, we observed 14 significant associations from three loci (Fig. 4e-f; Supplementary Table 1; Supplementary Table 5). Within this region, our strongest association was observed with the precuneus SA (rs73313052: P_{phase2} = 1.7 x 10^{-23}; P_{rep} = 2.5 x 10^{-35}; variance explained = 0.28%). rs73313052 is located between *DACT1* and *DAAM1*, both of which are involved in synapse formation and are critical members of the Wnt signalling cascade[39,40]. rs73313052 is an eQTL for *DAAM1* in adult cortex (FDR P_{CMC_SVA} = 0.009), with high LD proxies located within an active transcription start site in adult cortex and fetal brain tissue (Fig. 4e; Supplementary Table 10-11). Consistent with enrichment in the pathway analyses, a number of other loci were located in regions with functional links to genes involved in Wnt signalling, including 1p13.2, where rs910697 (lingual SA, P_{phase2} = 5.0 x 10^{-11}; P_{rep} = 1.1 x 10^{-11}; a synonymous SNP in *WNT2B* exon 4) and rs2999158 (pericalcarine SA, P_{phase2} = 2.0 x 10^{-12}; P_{rep} = 1.1 x 10^{-15}) are cortical eQTLs for *ST7L* and *WNT2B* (FDR P_{CMC_SVA} = 0.009; Supplementary Table 10–11).

A number of other regional associations occur near genes with known roles in brain development. For example, on chromosome 1p22.2, rs1413536 (inferior parietal SA: P_{phase2} = 9.7 x 10^{-13}; P_{rep} = 2.8 x 10^{-14}) is a cortical eQTL for *LMO4* (FDR P_{CMC_SVA} = 0.049). There are chromatin interactions between the region housing both this SNP and rs11161942 (posterior cingulate SA: P_{phase2} = 2.8 x 10^{-10}; P_{rep} = 4.4 x 10^{-10}) and the *LMO4* promoter in neural progenitor cells (Supplementary Table 10-11). *Lmo4* is one of the few genes already known to be involved in areal identity specification in mammalian brain[41].



Fig. 4 | Genetics of Regional Measures. a, Regional plot for rs1080066; **b**, Association of rs1080066 (G allele) with SA of cortical regions; **c**, Sun plot showing brain regions associated with 15q14, colours indicate different LD blocks; **d**, Association of rs1080066 with the depth of the central sulcus, and comparison of central sulcus depth across humans and other primate species; **e**, Regional plot for rs73313052; **f**, Association of rs73313052 (A allele) with SA of cortical regions; **g**, Sun plot showing brain regions associated with 14q23.1, colours indicate different LD blocks; **h**, Regional plot for rs6505147. Within the regional plots the three panels

contain: **i)** proxy SNPs and surrounding genes; **ii)** Chromatin state in four RoadMap brain tissues: dorsolateral prefrontal cortex (DPfC), fetal brain (female, Fet-F, and male, Fet-M) and NH-A_astrocytes_primary_cells (NH-A APC). **iii)** BRAINSPAN candidate gene expression in fetal and adult brain tissue (Supplementary Note).

Another locus of interest is chromosome 17q11.2 (Fig. 4g) where the lead variant, rs6505147 (P_{phase2} = 4.0 x 10^{-13}; P_{rep} = 1.2 x 10^{-12}), is associated with the insular SA. Located in *EFCAB5*, rs6505147 is centromeric to the serotonin transporter *SLC6A4.* Both *SLC6A4* and the insula have been implicated in mood disorders (although support for SLC6A4 is equivocal)[42-44]. rs6505147 is in a large LD block that extends to *SLC6A4*, but is not in LD (r^2=.06) with the highly investigated 5-HTTLPR repeat polymorphism that is within *SLC6A4* (see Methods). rs6505147 is a cortical eQTLs in multiple databases for six genes flanking *SLC6A4* (*CORO6*, *SSH2*, *EFCAB5*, *BLMH*, *GOSR1*, *SUZ12P*), but not for *SLC6A4* itself (Supplementary Table 10–11). While the LD structure at this locus complicates the assignment of a candidate gene (Methods), increased *EFCAB5* expression was recently associated with delayed brain aging, highlighting a possible role for this gene in the human aging[45].

Genetic relationships with neuropsychiatric disorders and psychological traits

To examine shared genetic effects between cortical structure and other traits, we performed genetic correlation analyses with GWAS summary statistics from 24 selected traits (Methods). We observed significant positive genetic correlations between total SA and general cognitive function[28], educational attainment[24], and Parkinson's disease[23]. For total SA, significant negative genetic correlations were detected with insomnia[46], attention deficit hyperactivity disorder[47] (ADHD), depressive symptoms[48], major depressive disorder[49], and neuroticism[25]. Genetic correlations with average TH did not survive multiple testing correction due to the weaker genetic association seen in the TH analyses (Fig. 5; Supplementary Table 14). We mapped genetic correlation patterns across the cortical regions without correction for the global measures to map the magnitude of these effects across the brain. No additional neuropsychiatric or psychological traits were significant at a regional level.



Fig. 5 | Genetic correlations with neuropsychiatric and psychological traits. a, genetic correlations with total SA and average TH positive correlations are shown in red, while negative correlations are shown in blue; **b**, regional variation in the strength of genetic correlations between regional surface area (without correction for total surface area) and traits showing significant genetic correlations with total surface area.

Discussion

Here we present a large-scale collaborative investigation of the effects of common genetic variation on human cortical structure using data from 51,238 individuals from 58 cohorts from around the world. We identify specific loci influencing cortical surface area (with 140 loci surviving multiple testing) and thickness (10 loci), implicating genes involved in areal patterning and cortical development. Our results support the radial unit hypothesis of surface area expansion in humans[3]: genetic variation within regulatory elements in fetal neural progenitor cells[19] is associated with variability in adult cortical surface area. We also find that Wnt signalling genes influence areal expansion in humans, as has been reported in model organisms such as mice[9]. Cortical thickness was associated with loci near genes implicated in cell differentiation, migration, adhesion, and myelination. Consequently, molecular studies in the appropriate tissues, such as neural progenitor cells and their differentiated neurons, will be critical to map the involvement of specific genes. Genetic variation associated with brain structure is functionally relevant, as evidenced by genetic correlations with a range of

neuropsychiatric disorders and psychological traits, including general cognitive function, Parkinson's disease, depression, ADHD and insomnia. This work identifies novel genome-wide significant loci associated with cortical surface area and thickness based on the largest imaging genetics study to date, providing a deeper understanding of the genetic architecture of the human cerebral cortex and its patterning.

References

1 Fischl, B. FreeSurfer. *Neuroimage* **62**, 774-781, doi:10.1016/j.neuroimage.2012.01.021 (2012).

2 Lui, J. H., Hansen, D. V. & Kriegstein, A. R. Development and evolution of the human neocortex. *Cell* **146**, 18-36, doi:10.1016/j.cell.2011.06.030 (2011).

3 Rakic, P. Specification of cerebral cortical areas. *Science* **241**, 170-176 (1988).

4 Cox, S. R. *et al.* Brain cortical characteristics of lifetime cognitive ageing. *Brain Struct Funct* **223**, 509-518, doi:10.1007/s00429-017-1505-0 (2018).

5 Karama, S. *et al.* Childhood cognitive ability accounts for associations between cognitive ability and brain cortical thickness in old age. *Mol Psychiatry* **19**, 555-559, doi:10.1038/mp.2013.64 (2014).

6 Hazlett, H. C. *et al.* Early brain development in infants at high risk for autism spectrum disorder. *Nature* **542**, 348-351, doi:10.1038/nature21369 (2017).

7 Winkler, A. M. *et al.* Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. *Neuroimage* **53**, 1135-1146, doi:10.1016/j.neuroimage.2009.12.028 (2010).

8 Strike, L. T. *et al.* Genetic Complexity of Cortical Structure: Differences in Genetic and Environmental Factors Influencing Cortical Surface Area and Thickness. *Cereb Cortex*, doi:10.1093/cercor/bhy002 (2018).

9 Harrison-Uy, S. J. & Pleasure, S. J. Wnt signaling and forebrain development. *Cold Spring Harb Perspect Biol* **4**, a008094, doi:10.1101/cshperspect.a008094 (2012).

10 Bae, B. I., Jayaraman, D. & Walsh, C. A. Genetic changes shaping the human brain. *Dev Cell* **32**, 423-434, doi:10.1016/j.devcel.2015.01.035 (2015).

11 Meechan, D. W., Maynard, T. M., Tucker, E. S. & LaMantia, A. S. Three phases of DiGeorge/22q11 deletion syndrome pathogenesis during brain development: patterning, proliferation, and mitochondrial functions of 22q11 genes. *Int J Dev Neurosci* **29**, 283-294, doi:10.1016/j.ijdevneu.2010.08.005 (2011).

12 Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage* **31**, 968-980, doi:10.1016/j.neuroimage.2006.01.021 (2006).

13 Nyholt, D. R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet* **74**, 765-769, doi:10.1086/383251 (2004).

14 Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat Neurosci* **19**, 1523-1536, doi:10.1038/nn.4393 (2016).

15 Ikram, M. A. *et al.* Common variants at 6q22 and 17q21 are associated with intracranial volume. *Nat Genet* **44**, 539-544, doi:10.1038/ng.2245 (2012).

16 Adams, H. H. *et al.* Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nat Neurosci* **19**, 1569-1582, doi:10.1038/nn.4398 (2016).

17 Hibar, D. P. *et al.* Common genetic variants influence human subcortical brain structures. *Nature* **520**, 224-229, doi:10.1038/nature14101 (2015).

18 Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat Genet* **50**, 621-629, doi:10.1038/s41588-018-0081-4 (2018).

19 de la Torre-Ubieta, L. *et al.* The Dynamic Landscape of Open Chromatin during Human Cortical Neurogenesis. *Cell* **172**, 289-304.e218, doi:10.1016/j.cell.2017.12.014 (2018).

20 Kundaje, A. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317-330, doi:10.1038/nature14248 (2015).

21 Ronan, J. L., Wu, W. & Crabtree, G. R. From neural development to cognition: unexpected roles for chromatin. *Nat Rev Genet* **14**, 347-359, doi:10.1038/nrg3413 (2013).

22 Silbereis, J. C., Pochareddy, S., Zhu, Y., Li, M. & Sestan, N. The Cellular and Molecular Landscapes of the Developing Human Central Nervous System. *Neuron* **89**, 248-268, doi:10.1016/j.neuron.2015.12.008 (2016).

23 Nalls, M. A. *et al.* Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet* **46**, 989-993, doi:10.1038/ng.3043 (2014).

24 Okbay, A. *et al.* Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* **533**, 539-542, doi:10.1038/nature17671 (2016).

25 Luciano, M. *et al.* Association analysis in over 329,000 individuals identifies 116 independent variants influencing neuroticism. *Nat Genet* **50**, 6-11, doi:10.1038/s41588-017-0013-8 (2018).

26 Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nature Communications* **8**, 1826, doi:10.1038/s41467-017-01261-5 (2017).

27 Duarte, R. R. R. *et al.* Genome-wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain. *Am J Med Genet B Neuropsychiatr Genet* **171**, 806-814, doi:10.1002/ajmg.b.32445 (2016).
28 Sniekers, S. *et al.* Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. *Nat Genet* **49**, 1107-1112, doi:10.1038/ng.3869 (2017).
29 Won, H. *et al.* Chromosome conformation elucidates regulatory relationships in developing human brain. *Nature* **538**, 523-527, doi:10.1038/nature19847 (2016).
30 Baala, L. *et al.* Homozygous silencing of T-box transcription factor EOMES leads to microcephaly with polymicrogyria and corpus callosum agenesis. *Nat Genet* **39**, 454-456, doi:10.1038/ng1993 (2007).
31 DiGiacomo, V. & Meruelo, D. Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein. *Biol Rev Camb Philos Soc* **91**, 288-310, doi:10.1111/brv.12170 (2016).
32 Reck-Peterson, S. L., Redwine, W. B., Vale, R. D. & Carter, A. P. The cytoplasmic dynein transport machinery and its many cargoes. *Nat Rev Mol Cell Biol* **19**, 382-398, doi:10.1038/s41580-018-0004-3 (2018).
33 van der Sluis, S., Posthuma, D. & Dolan, C. V. TATES: efficient multivariate genotype-phenotype analysis for genome-wide association studies. *PLoS genetics* **9**, e1003235, doi:10.1371/journal.pgen.1003235 (2013).
34 Chenn, A. & Walsh, C. A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. *Science* **297**, 365-369, doi:10.1126/science.1074192 (2002).
35 Munji, R. N., Choe, Y., Li, G., Siegenthaler, J. A. & Pleasure, S. J. Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **31**, 1676-1687, doi:10.1523/jneurosci.5404-10.2011 (2011).
36 Aschard, H., Vilhjalmsson, B. J., Joshi, A. D., Price, A. L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet* **96**, 329-339, doi:10.1016/j.ajhg.2014.12.021 (2015).
37 Cykowski, M. D. *et al.* The central sulcus: an observer-independent characterization of sulcal landmarks and depth asymmetry. *Cereb Cortex* **18**, 1999-2009, doi:10.1093/cercor/bhm224 (2008).
38 Hopkins, W. D. *et al.* Evolution of the central sulcus morphology in primates. *Brain Behav Evol* **84**, 19-30, doi:10.1159/000362431 (2014).
39 Okerlund, N. D. *et al.* Dact1 is a postsynaptic protein required for dendrite, spine, and excitatory synapse development in the mouse forebrain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **30**, 4362-4368, doi:10.1523/jneurosci.0354-10.2010 (2010).
40 Habas, R., Kato, Y. & He, X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. *Cell* **107**, 843-854 (2001).
41 Huang, Z. *et al.* Transcription factor Lmo4 defines the shape of functional areas in developing cortices and regulates sensorimotor control. *Dev Biol* **327**, 132-142, doi:10.1016/j.ydbio.2008.12.003 (2009).
42 Culverhouse, R. C. *et al.* Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. *Mol Psychiatry* **23**, 133-142, doi:10.1038/mp.2017.44 (2018).
43 Sliz, D. & Hayley, S. Major depressive disorder and alterations in insular cortical activity: a review of current functional magnetic imaging research. *Front Hum Neurosci* **6**, 323, doi:10.3389/fnhum.2012.00323 (2012).
44 Hibar, D. P. *et al.* Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Mol Psychiatry* **23**, 932-942, doi:10.1038/mp.2017.73 (2018).
45 Lu, A. T. *et al.* Genetic architecture of epigenetic and neuronal ageing rates in human brain regions. *Nat Commun* **8**, 15353, doi:10.1038/ncomms15353 (2017).
46 Hammerschlag, A. R. *et al.* Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. *Nat Genet* **49**, 1584-1592, doi:10.1038/ng.3888 (2017).
47 Demontis, D. *et al.* Discovery Of The First Genome-Wide Significant Risk Loci For ADHD. *bioRxiv*, doi:10.1101/145581 (2017).
48 Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat Genet* **48**, 624-633, doi:10.1038/ng.3552 (2016).
49 Wray, N. R. *et al.* Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature Genetics* **50**, 668-681, doi:10.1038/s41588-018-0090-3 (2018).

Methods

Ethical approval and data availability

Participants in all cohorts in this study gave written informed consent and sites involved obtained approval from local research ethics committees or Institutional Review Boards. Ethics approval for the meta-analysis was granted by the QIMR Berghofer Medical Research Institute Human Research Ethics Committee (approval: *P2204*). The meta-analytic results will be available to download from the ENIGMA consortium webpage upon publication http://enigma.ini.usc.edu/research/download-enigma-gwas-results.

Imaging

Measures of cortical surface area (SA) and thickness (TH) were derived from *in-vivo* whole brain T1-weighted magnetic resonance imaging (MRI) scans using FreeSurfer MRI processing software[1] (see Supplementary Table 3). SA and TH were quantified for each subject within 34 distinct gyral-defined regions in each brain hemisphere according to the Desikan-Killiany atlas[12] (Fig. 1a). SA was measured at the grey-white matter boundary. TH was measured as the average distance between the white matter and pial surfaces. The total SA and average TH of each hemisphere was computed separately. High test-retest correlations have been reported for all measures with the exception of the frontal and temporal poles[8]. Image processing and quality control were implemented at the cohort level following detailed, harmonized protocols (see http://enigma.ini.usc.edu/protocols/imaging-protocols/ for protocols); phenotype distributions for all traits in all cohorts were inspected centrally prior to meta-analysis any cohort where the phenotypic distribution for a given trait showed deviation from expectations that could not be resolved through reanalysis or outlier inspection were excluded from analyses of that trait.

Genome-wide association analyses

At each site, genotypes were imputed using either the 1000 Genomes Project[50] or Haplotype Reference Consortium[51] references (Supplementary Table 4). To ensure consistency in the correction for ancestry and stability of the correction given the relatively small sample sizes, each cohort also ran the same multidimensional scaling (MDS) analysis protocol in which the data from the HapMap 3 populations were merged with the site level data and MDS components were calculated across this combined data set. Within each cohort, genome-wide association (GWAS) was conducted using an additive model including covariates to control for the effects of age, sex, ancestry (the first four MDS components), diagnostic status (when the cohort followed a case-control design), and scanner (when multiple scanners were used at the same site).

The primary GWAS of regional measures included the global measure of SA or TH as an additional covariate, to test for genetic influences specific to each region. However, to aid interpretation, the regional GWAS were also run without controlling for global measures. Cohort level GWAS results underwent quality control (excluding variants with an imputation $R^2 \leq .5$ and MAF $\leq .005$). Across all cohorts, for each phenotype, GWAS summary plots (Manhattan and QQ plots) were visually inspected by the central analysis group, if a given trait showed deviation from expectations that could not be resolved through reanalysis that cohort was excluded from analyses of that trait. Given the large disparity in sample size (and corresponding fluctuation in power) between indels and SNPs (see UK Biobank data below), we only carried forward SNPs within the meta-analyses.

Multiple testing correction

We analysed 70 traits (total SA, average TH, and the SA and TH of 34 cortical regions averaged across right and left). However, after accounting for the correlation between the traits in the UK Biobank (residuals correcting for sex, age, ancestry and global measures) using matrix spectral decomposition (matSpD[13]) the effective number of traits was estimated to be 60. Therefore, we applied the significance threshold of $P \leq 8.3 \times 10^{-10}$ to correct for multiple testing in the GWAS meta-analysis results. Multiple testing corrections applied to each of the follow-up analyses are described below.

Meta-analysis

A rolling meta-analytic approach was used, where three phases of meta-analysis were conducted. The meta-analytic workflow is described in Supplementary Fig. 1 and cohort information is provided in Supplementary Table 2. All meta-analyses were conducted using METAL[52]. The results of the meta-analysis are summarized in Supplementary Table 5. For meta-analyses phases 1-3 we used standard error weighted meta-analyses. In the additional replication step, we used sample size weighted meta-analyses, in order to include results from the CHARGE consortium for which only sample size weighted results were available. For each meta-analysis, the results were quality controlled, removing strand ambiguous SNPs where the effect allele frequency crossed .5, and variants where the total sample size was < 10,000 for phases 1-3.

We visually inspected the frequencies of effect alleles of all nominally genome-wide significant ($P \leq 5 \times 10^{-8}$) variants that were strand ambiguous. Three variants (rs10237366: lingual and pericalcarine SA, rs2269084:

paracentral SA, rs4515470: superior temporal SA) showed allele frequency patterns that could not be disambiguated for one or more of the non-European cohorts. In these cases, the data for the variant within the cohort(s) that could not be resolved were dropped and the meta-analysis was re-run.

Following Rietveld et al[53], we estimated the variance explained R^2 by each variant j as:

$$R_j^2 \approx \frac{2p_j q_j . \hat{\beta}_j^2}{\hat{\sigma}_y^2}$$

where p_j and q_j are the minor and major allele frequencies, $\hat{\beta}_j$ is the estimated effect of the variant within the meta-analysis and $\hat{\sigma}_y^2$ is the estimated variance of the trait (for which we used the pooled variance of the trait across all ENIGMA cohorts and UK Biobank; see Supplementary Table 1). To obtain beta and standard error estimates from the results from the sample size weighted meta-analyses reported in Supplementary Table 5 we used the following equations from Rietveld et al[53]:

$$\hat{\beta}_j \approx z_j \cdot \frac{\hat{\sigma}_y}{\sqrt{N_j \cdot 2p_j q_j}} \text{ and } SE(\hat{\beta}_j) \equiv \frac{z_j}{\hat{\beta}_j}$$

Where z_j is the Z-score and SE($\hat{\beta}_j$) is the estimated standard effect of the variant within the meta-analysis and N is the number of contributing alleles.

Analyses of UK Biobank data

Analyses of the UK Biobank cohort were conducted on the 2017 imputed genotypes restricted to variants present in the Haplotype Reference Consortium[51]. UK Biobank bulk imaging data were made available for 12,962 individuals under application #11559 in July 2017. We processed the raw MRI data using the ENIGMA protocols. Following processing, all images were visually inspected. Analyses of UK Biobank participants within .02 on the first and second MDS components of the European centroid were included in the phase 1 meta-analyses of the European ancestry cohorts (Supplementary Fig. 1). Analyses of participants beyond this threshold were included in the phase 3 meta-analyses of non-European ancestry cohorts (see Supplementary Fig. 1).

Gene-based association analyses

We conducted genome-wide gene-based association analysis using the second phase of the meta-analytic results. We used the 19,427 protein-coding genes from the NCBI 37.3 gene definitions as the basis for the gene-based association analysis using MAGMA[54]. We selected for each gene all SNPs within exonic, intronic and untranslated regions of the gene as well as SNPs within 50 kb downstream and upstream of the gene. After SNP annotation, there were 18,295 genes that were covered by at least one SNP. Gene-based association tests were performed taking LD between SNPs into account. We applied a Bonferroni correction to account for multiple testing, adjusting for the number of genes tested as well as the number of traits tested (60 independent traits), setting the genome-wide threshold for significance at 4.5×10^{-8}. These results are shown in Supplementary Table 6.

Heritability due to common variants, genetic correlations and partitioned heritability

We used LD score regression[55,56] to estimate the proportion of variance accounted for by common SNPs or SNP heritability (h^2_{SNP}) of the global measures (total SA and average TH) and the SA and TH of each of the 34 cortical regions. These results are shown in Supplementary Table 7. LD score regression[56] was also used to estimate genetic correlations between regions and with global measures. These results are shown in Supplementary Table 12-13. We used a threshold of $P \leq 8.3 \times 10^{-4}$ (0.05/60) to correct for multiple testing in the genetic and phenotypic correlations shown in Fig. 3. To identify patterns of genetic correlations of SA and TH (both with and without correction for global measures), we used Mclust[57] for hierarchical cluster analysis, which uses expectation-maximisation to fit parameterized Gaussian mixture models to the data. The best-fitting model for number and shape of clusters was selected as the one with the largest Bayesian Information Criterion. These results are shown in Supplementary Fig. 3.

Partitioned heritability analysis was used to estimate the percentage of heritability explained by annotated regions of the genome[58]. Annotations were derived from either Epigenomics Roadmap[59]or a study of chromatin accessibility in mid-fetal brains[19]. For analyses using Epigenomics Roadmap data, chromatin states (15 state model) were downloaded for available tissue types (http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html). For each tissue, genomic regions comprising all active regulatory elements (TssA, TssAflnk, Enh, EnhG) within each tissue type were added as an additional annotation to the baseline model provided with the LDSC package (https://github.com/bulik/ldsc). For analyses using chromatin accessibility in mid-fetal brains, the genomic coordinates of peaks more accessible in the germinal zone than the cortical plate (GZ>CP) and peaks more accessible in the cortical plate than the germinal zone (CP>GZ) were added separately to the baseline annotations. Partitioned

heritability and the enrichment of heritability explained in these annotations was run using LD-score regression[58]. The significance of enrichment was corrected across all annotations used (including those not displayed) using false discovery rate (FDR) and the enrichment scores were plotted as a heatmap for those that survived significance (Fig. 2b).

Genetic correlations were calculated to determine if shared genetic influences contributed to both cortical structure and neuropsychiatric disorders or psychological traits. Summary statistics were downloaded from the following published genome-wide association studies: general cognitive function[28], insomnia[46], antisocial behavior[60], educational attainment[24], subjective well-being[48], depressive symptoms[48], neuroticism[25], attention deficit hyperactivity disorder (ADHD)[47], autism[61], bipolar disorder[62], anorexia nervosa[63], major depressive disorder[49], obsessive compulsive disorder[64], post-traumatic stress disorder (PTSD)[65], schizophrenia[66], anxiety disorders[67], aggression[68], Alzheimer's disease[69], loneliness[70], cigarettes smoked per day[71], epilepsy[72], Parkinson's disease[23], frontotemporal dementia[73], and irritable bowel disease[74]. LD-score regression was used to calculate genetic correlations[56]. Significance was corrected for multiple comparisons using FDR across all genetic correlations with average TH and total SA, and significant associations were highlighted in Fig. 5. To explore regional variability in those significant genetic correlations, genetic correlations were conducted between the trait and the cortical regions (without correcting for global measures). These results are shown in Supplementary Tables 8 and 14.

Multivariate GWAS analysis

We used TATES[33] to conduct two multivariate analyses: one for the 34 regional SA measures, and one for the 34 regional TH measures. These analyses were run on the meta-analytic results from the second phase of meta-analysis. Briefly, TATES combines the *p*-values from univariate GWAS while correcting for the phenotypic correlations between traits and does not require access to raw genotypic data[33]. The power of TATES has been shown to be similar or greater than that of multivariate tests using raw data across a range of scenarios for analyses of 20 or more traits[75]. For these analyses, we used phenotypic correlations calculated from the UK Biobank cohort (residuals correcting for sex, age, ancestry, and global brain measures).

Gene-set enrichment analyses

Gene-set enrichment analyses were performed on total SA and average TH as well as the multivariate GWAS results for SA and TH using DEPICT[76]. Within DEPICT, groups of SNPs were assessed for enrichment in 14,462 gene-sets. These analyses were run using variants with $P \leq 1.0 \times 10^{-5}$. Gene-set enrichment analyses were considered significant if they survived FDR correction ($q \leq 0.05$)[76]. These results are shown in Supplementary Table 9.

Functional annotation

Potential functional impact was investigated for each of the 251 SNPs nominally associated with global and regional SA and TH and for their proxies (defined here as $r^2 > 0.6$ to the lead SNP) using a number of publicly available data sources. The majority of the SNP annotations were as provided by FUMA[26] which annotates SNP location (e.g., genic/intergenic), the potential for functional effects through predicted effects as determined by CADD[77] and Regulome[78], expression quantitative trait (eQTL) effects (e.g., GTEx, the UK Brain Expression Consortium (http://www.braineac.org/), and the CommonMind Consortium[81]), and chromatin state and interactions in numerous tissues (data from 21 tissue/cell types, GEO GSE87112). These data were used by FUMA to map coding and non-coding (e.g., lincRNA) genes to each lead SNP based on an eQTL effect with an FDR correction $P \leq 0.05$ in cortical tissue, and/or chromatin interactions between the region harbouring the lead SNP and a gene promoter in a second chromosomal region (including interactions with an FDR correction $P \leq 1 \times 10^{-6}$) in dorsolateral prefrontal cortex and neural progenitor cells[26]. HaploReg[79] was used to annotate transcription factor binding across multiple tissues, and whether SNPs modified transcription factor binding motifs. The potential for a detrimental effect on protein function due to lead or proxy SNPs located within gene exons was investigated using SIFT and PolyPhen as reported by SNPNexus[80]. Pre- and post-natal gene expression data across multiple brain regions was obtained from the BrainSpan Atlas of the Developing Human Brain (http://www.brainspan.org/). Summaries of the functional annotation data are presented in Supplementary Tables 10–11.

Analysis of the central sulcus

To follow-up the precentral surface area association with rs1080066, 10,557 UK Biobank MRI scans were further analyzed using BrainVISA-4.5 Morphologist pipeline for the extraction and parameterization of the central sulcus. Quality controlled FreeSurfer outputs (orig.mgz, ribbon.mgz and talairach.auto) were directly imported into the pipeline to use the same gray and white matter segmentations. Sulci were automatically labeled according to a predefined anatomical nomenclature of 60 sulcal labels per hemisphere[81,82]. Extracted meshes for the left and right central sulcus were visually quality checked; subjects with mislabelled central sulcus were discarded from further analysis; 6,045 individuals had good quality extractions for both the left and right hemispheres. The central sulcus depth profile was measured by extending the method introduced in[37,83].

The ridges at the fundus of the sulcus and at the convex hull, along with the two extremities, were automatically extracted. Using these landmarks, two coordinate fields (x and y) were extrapolated over the entire mesh surface[84]. Sulcal depth was defined as the distance between paired points at the sulcal fundus and brain envelope that shared the same y coordinate[85]. For each individual, the parametrized surface was divided into 100 equally spaced points along the length of the sulcus, and the depth at each point was recorded for comparison. We averaged the corresponding depth measurements across the left and right sulcus and calculated the effect of the rs1080066 G allele on the bilaterally averaged depth at each point. These results are shown in Fig. 4d.

Estimating linkage disequilibrium (LD) with the 5-HTTLPR variable number tandem repeat.
Using PLINK[86], we estimated the LD between rs6505147 and the 5-HTTLPR variable number tandem repeat using data from 807 unrelated founders from the QTIM sample who are genotyped for 5-HTTLPR and have rs6505147 imputed (imputation accuracy r^2 = 0.965). These analyses showed the two genotypes to be unlinked, R^2 = 0.066, D' = 0.267.

References

50 The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68, (2015).
51 McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nature genetics* **48**, 1279-1283, doi:10.1038/ng.3643 (2016).
52 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
53 Rietveld, C. A. *et al.* GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment. *Science (New York, N.Y.)* **340**, 1467-1471, doi:10.1126/science.1235488 (2013).
54 de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219, doi:10.1371/journal.pcbi.1004219 (2015).
55 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295, doi:10.1038/ng.3211 (2015).
56 Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).
57 Scrucca, L., Fop, M., Murphy, T. B. & Raftery, A. E. mclust 5: Clustering, Classification and Density Estimation Using Gaussian Finite Mixture Models. *The R journal* **8**, 289-317 (2016).
58 Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet* **47**, 1228-1235, doi:10.1038/ng.3404 (2015).
59 Roadmap Epigenomics Consortium. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317-330, doi:10.1038/nature14248 (2015).
60 Tielbeek, J. J. *et al.* Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior. *JAMA Psychiatry* **74**, 1242-1250, doi:10.1001/jamapsychiatry.2017.3069 (2017).
61 Grove, J. *et al.* Common risk variants identified in autism spectrum disorder. *bioRxiv*, doi:10.1101/224774 (2017).
62 Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* **43**, 977-983, doi:10.1038/ng.943 (2011).
63 Duncan, L. *et al.* Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. *Am J Psychiatry* **174**, 850-858, doi:10.1176/appi.ajp.2017.16121402 (2017).
64 International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry* **23**, 1181-1188, doi:10.1038/mp.2017.154 (2018).
65 Duncan, L. E. *et al.* Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. *Mol Psychiatry* **23**, 666-673, doi:10.1038/mp.2017.77 (2018).
66 Pardinas, A. F. *et al.* Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet* **50**, 381-389, doi:10.1038/s41588-018-0059-2 (2018).
67 Otowa, T. *et al.* Meta-analysis of genome-wide association studies of anxiety disorders. *Mol Psychiatry* **21**, 1391-1399, doi:10.1038/mp.2015.197 (2016).
68 Pappa, I. *et al.* A genome-wide approach to children's aggressive behavior: The EAGLE consortium. *Am J Med Genet B Neuropsychiatr Genet* **171**, 562-572, doi:10.1002/ajmg.b.32333 (2016).
69 Lambert, J. C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-1458, doi:10.1038/ng.2802 (2013).

70 Gao, J. *et al.* Genome-Wide Association Study of Loneliness Demonstrates a Role for Common Variation. *Neuropsychopharmacology* **42**, 811-821, doi:10.1038/npp.2016.197 (2017).
71 Tobacco & Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet* **42**, 441-447, doi:10.1038/ng.571 (2010).
72 International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. *Lancet Neurol* **13**, 893-903, doi:10.1016/S1474-4422(14)70171-1 (2014).
73 Ferrari, R. *et al.* Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol* **13**, 686-699, doi:10.1016/s1474-4422(14)70065-1 (2014).
74 Jostins, L. *et al.* Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* **491**, 119-124, doi:10.1038/nature11582 (2012).
75 Porter, H. F. & O'Reilly, P. F. Multivariate simulation framework reveals performance of multi-trait GWAS methods. *Sci Rep* **7**, 38837, doi:10.1038/srep38837 (2017).
76 Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat Commun* **6**, 5890, doi:10.1038/ncomms6890 (2015).
77 Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* **46**, 310-315, doi:10.1038/ng.2892 (2014).
78 Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res* **22**, 1790-1797, doi:10.1101/gr.137323.112 (2012).
79 Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* **40**, D930-934, doi:10.1093/nar/gkr917 (2012).
80 Chelala, C., Khan, A. & Lemoine, N. R. SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. *Bioinformatics* **25**, 655-661, doi:10.1093/bioinformatics/btn653 (2009).
81 Perrot, M., Riviere, D. & Mangin, J. F. Cortical sulci recognition and spatial normalization. *Medical image analysis* **15**, 529-550, doi:10.1016/j.media.2011.02.008 (2011).
82 Riviere, D. *et al.* Automatic recognition of cortical sulci of the human brain using a congregation of neural networks. *Medical image analysis* **6**, 77-92 (2002).
83 Hopkins, W. D., Coulon, O. & Mangin, J. F. Observer-independent characterization of sulcal landmarks and depth asymmetry in the central sulcus of the chimpanzee brain. *Neuroscience* **171**, 544-551, doi:10.1016/j.neuroscience.2010.07.018 (2010).
84 Coulon, O. *et al.* Cortical localization via surface parameterization: a sulcus-based approach. *Neuroimage* **31**, 29-185 (2006).
85 Coulon, O. *et al.* Two new stable anatomical landmarks on the Central Sulcus: definition, automatic detection, and their relationship with primary motor functions of the hand. *Conf Proc IEEE Eng Med Biol Soc* **2011**, 7795-7798, doi:10.1109/iembs.2011.6091921 (2011).
86 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-575, doi:10.1086/519795 (2007).

Extended Data Figures

Supplementary Figure 1. Flow chart summarising the phases of meta-analysis.

Supplementary Figure 2. Results of co-localisation analyses for a) the 17q21.31 inversion region and b) the 6q21 region.

Supplementary Figure 3. Clustering of genetic correlations among a) surface area and b) thickness regions after correcting for global measures. Clustering of genetic correlations among c) surface area and d) thickness regions without correcting for global measures. The best-fitting model for surface area with global correction was 3 diagonal components with varying volume and shape, and for thickness was 6 spherical components with equal volume. The best-fitting model for surface area without global correction was 5 spherical components with varying volume, and for thickness was 8 spherical components with equal volume.

Supplementary Figure 4. P-value of genome-wide significant regional SNPs with global control compared to their P-value in the global measure for a) surface area and b) thickness. Effect size of genome-wide significant regional SNPs with global control compared to their effect size in global measures for c) surface area and d) thickness. Effect size of genome-wide significant regional SNPs with global control compared to regional SNPs without global control in e) surface area and f) thickness.

Supplementary Figure 5. Regional association plot for the 3p24.1 locus (rs12630663)

Supplementary Notes

Functional annotation

Chromatin state represents the degree to which 200 bp genomic regions are accessible for transcription. Around each of our associated loci, chromatin state was annotated by FUMA[26] utilising the core 15-state model as predicted by Roadmap Epignomics using ChromHMM, based on data for 5 chromatin state marks (H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3) in 127 epigenomes[20]. In Fig. 5, genomic regions in three tissues/cells most relevant to our study (RoadMap E073 dorsolateral prefrontal cortex [Adult cortex], E081 female fetal brain [Fetal brain], and E125 NH-A Astrocytes Primary Cells [Astrocytes]) are indicated as one of the 15 possible chromatin states, as outlined in Table 1.

Table 1. RoadMap Core 15-chromatin state model abbreviations and descriptors

STATE #	Abbreviation	Description
1	TssA	Active Transcription Start Site (TSS)
2	TssAFlnk	Flanking Active TSS
3	TxFlnk	Transcription at gene 5' and 3'
4	Tx	Strong transcription
5	TxWk	Weak transcription
6	EnhG	Genic enhancers
7	Enh	Enhancers
8	ZNF/Rpts	ZNF genes & repeats
9	Het	Heterochromatin
10	TssBiv	Bivalent/Poised TSS
11	BivFlnk	Flanking Bivalent TSS/Enhancer
12	EnhBiv	Bivalent Enhancer
13	ReprPC	Repressed PolyComb
14	ReprPCWk	Weak Repressed PolyComb
15	Quies	Quiescent/Low

To aid in the identification of candidate genes influencing cortical development we examined gene expression levels in pre- and post-natal brains for each of the genes of interest (primarily cortical eQTLs and/or genes with a known brain association/function) flanking our associated loci. Here we used data included in the Developmental Transcriptome portal of the BRAINSPAN Atlas of the Developing Human Brain website (http://www.brainspan.org/rnaseq/searches?search_type=user_selections). These data include gene expression information for cortical tissues indicated on a scale from low (dark blue) to high (dark red) expression on a $\log_2$ RPKM scale (RPKM = Reads Per Kilobase [of transcript per] Million [mapped reads], which normalises expression levels to account for sequencing depth and gene length). The BRAINSPAN cortical tissues, organised in ontological order, are as outlined in Table 2.

Table 2. Brainspan cortical tissues abbreviations and descriptors

Abbreviation	Description
DFC	dorsolateral prefrontal cortex
VFC	ventrolateral prefrontal cortex
MFC	anterior (rostral) cingulate (medial prefrontal) cortex
OFC	orbital frontal cortex
M1C	primary motor cortex (area M1, area 4)
M1C-S1C	primary motor-sensory cortex (samples)
PCx	parietal neocortex
S1C	primary somatosensory cortex (area S1, areas 3,1,2)
IPC	posteroventral (inferior) parietal cortex
A1C	primary auditory cortex (core)
TCx	temporal neocortex
STC	posterior (caudal) superior temporal cortex (area 22c)
ITC	inferolateral temporal cortex (area TEv, area 20)
Ocx	occipital neocortex
V1C	primary visual cortex (striate cortex, area V1/17)

For each locus, we evaluated functional annotations for the lead SNP and for additional SNPs considered to be credible causal variants (CCVs) if they were either i) in reasonable LD ($R^2 \geq 0.6$ in individuals of European

ancestry) with the lead SNP and/or ii) had P-values within 2 orders of magnitude of the lead SNP. As lincRNAs show considerable cell/tissue specificity, in the main text we detail SNP location based on neighbouring coding genes, but detail lincRNAs when our lead SNPs show eQTL effects and/or chromatin interactions to these non-coding transcripts.

Genes at each associated locus were determined to be potential candidates by considering whether the lead SNP (or a proxy) was an eQTL for a particular gene in adult cortical tissue (e.g. BRAINEAC, CMC or GTEx cortical tissues) and/or when chromatin interactions were observed to occur between the region harbouring the lead/proxy SNPs and a gene promoter in relevant brain tissues (dorsolateral prefrontal cortex and/or neural progenitor cells). For each of the loci shown in the main text we determined potential candidates as (but not limited to) the following:

Loci associated with Total Surface Area:

rs62057153, chromosome 17q21.31

Located in intron 4 of the Corticotropin Releasing Hormone Receptor 1(*CRHR1*) gene, lead SNP rs62057153 is in a large inversion region with extensive LD across ~0.45 Mb. Due to the LD structure there are > 4000 CCVs at this locus, making identification of a causal variant and its gene/s targets difficult. Of note, these CCVs are eQTLs (Supplementary Table 11) for 21 coding and non-coding genes in cortical tissue, including *CRHR1*[87] (FDR P_{CMC} = 0.009) and other genes known to be involved in brain development such as Wnt Family Member 3 (*WNT3*: FDR P_{CMC} = 0.009), Microtuble Associated Protein Tau (*MAPT*[88]: FDR P_{CMC} = 0.009) and KAT8 Regulatory NSL Complex Subunit 1 (*KANSL1*[89]: FDR P_{CMC} = 0.009) (Supplementary Table 11). Of the CCVs 59 are exonic variants: 5 of these are non-synonymous variants predicted to alter the function of *MAPT* (rs12185233, rs17651549, rs63750417), *KANSL1* (rs35833914) and *SPPL2C* (rs12373123).

rs1628768, chromosome 10q24.33

Lead SNP rs1628768 is located between the coding genes 5'-Nucleotidase, Cytosolic II (*NTC52*) and Internexin Neuronal Intermediate Filament Protein Alpha (*INA*). In addition to rs1628768 there are 22 additional CCVs at this locus, one of which (rs7911488) is located within ATP Synthase Membrane Subunit DAPIT *ATP5MD/USMG5* intron 1, in a region of histone binding indicating promoter and enhancer activity in dorsolateral prefrontal cortex and fetal brain (RoadMap Epigenome tissues E073, E082 and E081; Fig. 2d). There is evidence for an eQTL effect for *USMG5* and a number of additional genes in various non-brain tissues (Supplementary Table 11), while in cortical tissue these CCVs are eQTLs for *INA*, encoding the fourth subunit of neuronal filaments in the adult central nervous system[89], *C10orf32*, WW Domain Binding Protein 1 Like (*WBP1L*), and the schizophrenia candidate genes Arsenite Methyltransferase (*AS3MT*) and *NT5C2*[89].

rs2802295, chromosome 6q21

Lead SNP rs2802295 is located within intron 1 of the Forkhead Box O3 (*FOXO3*) gene. This SNP is a cortical eQTL for *FOXO3* and for Zinc Finger Protein 259 Pseudogene 1 (*ZNF259P1*; Supplementary Table 11). In mouse models *Foxo3* has been shown to be linked to numerous, including neuronal death and neurotoxic amyloid beta peptide processing in an Alzheimer's model[90]).

rs34464850, chromosome 3q23

Lead SNP rs34464850 is located within intron 4 of the Transcription Factor Dp-2 (*TFDP2*) gene. This SNP is an eQTL for ATPase Na+/K+ Transporting Subunit Beta 3 (*ATP1B3*), G Protein-Coupled Receptor Kinase 7 (*GRK7*) and *TFDP2* in whole blood (Supplementary Table 11).

rs190958130, chromosome 6q22.32

Eleven significant associations with various phenotypes were identified across the 6q22.32 region (Supplementary Table 10), comprising three independent genomic loci (R^2<0.4, Supplementary Table 10). Lead SNP rs190958130 is a low frequency variant (minor allele frequency (MAF) ~ 0.4) located between the Centromere Protein W (*CENPW*) and R-Spondin 3 (*RSPO3*) genes. This SNP is in very close proximity but low LD to a higher frequency SNP, rs4273712 (MAF ~ 0.37, $R^2_{rs190958130\text{-}rs4273712}$ = 0.011), associated with total, caudal middle frontal and parahippocampal SA in this study, and also previously associated with intracranial volume. *CENPW* is an interesting candidate as while a direct link between this gene and cortical development has not been reported, many other centrosomal proteins have been implicated in microcephaly[91], with alterations in centrosomal proteins impacting cell proliferation and hence cortex structure.

rs190958130 and rs4273712, chromosome 6q22.32

Lead SNP rs11171739 is located between the Ribosomal Protein S26 (*RPS26*) and Erb-B2 Receptor Tyrosine Kinase 3 (*ERBB3*) genes. This low frequency SNP (MAF = 0.04) is a cortical eQTL for *RPS26 (*$P_{GTEX\ Brain\ cortex}$ = 7.4 x 10^{-44}), *ERBB3* (FDR P_{CMC} = 0.009) and for Sulfite Oxidase (*SUOX*; $P_{GTEX\ Brain\ cortex}$ = 5.5 x 10^{-8}). In mice, Erbb3 has been shown to bind Erbb4, essential for neuronal survival[92]. *SUOX* mutations are responsible for

Isolated Sulphite Oxidase Deficiency, a neurometabolic disease with multiple neurological findings including substantial neuronal loss[93].

Lead SNP rs4273712 is also located between *CENPW* and *RSPO3* genes, although there is no LD between this common SNP and the lower frequency variant rs190958130. Proxy SNPs for rs4273712, along with other SNPs in the region associated with various other phenotypes (rs2184968 and rs9401907, pairwise R^2 between these SNPs ≤ 0.25; Supplementary Table 10), are cortical eQTLs for the TRNA Methyltransferase 11 Homolog (*TRMT11*: FDR P_{CMC} = 0.049) gene. This SNP was previously associated with intracranial volume[15].

Loci associated with Average Thickness:
rs630934, chromosome 3p22.1
Lead SNP rs630934 is located between the Ribosomal Protein SA (*RPSA*) and Myelin-Associated Oligodendroctye Basic Protein (*MOBP*) genes. *MOBP* is an interesting candidate gene for cortical thickness due to its role in myelination, and that expression is higher post- than pre-natally (Fig. 2f). However, an eQTL association with *MOBP* is seen only in GTEx tibial nerve tissue, with more extensive eQTL associations seen for other nearby genes, particularly *RPSA*, in other tissue types (Supplementary Table 11). *RPSA*, with functions as a ribosomal protein and a non-integrin laminin receptor, has been shown to have a role in neuronal migration through a functional interaction with *ZNF804A*[94]. There are no chromatin interactions or cortical eQTLs associated with rs630934 or its proxies in cortical data currently available in the FUMA database.

rs11692435, chromosome 2q11.2
Lead SNP rs11692435 is located within exon ARP1 Actin Related Protein 1 Homolog B (*ACTR1B*) gene. While there are other CCVs at this locus, rs11692435 is itself an interesting candidate causal SNP as it causes an amino acid replacement predicted to be 'damaging' to protein function by SIFT and 'probably damaging' by PolyPhen (http://www.snp-nexus.org/; Supplementary Table 10). This SNP and its proxies are eQTLs for *ACTR1B* and for other nearby genes in numerous tissues (Supplementary Table 11).

Regional Associations:
rs1080066, chromosome 15q14 (precentral SA, rostral middle frontal SA)
Located within intron 1 of lincRNA *RP11-624L4.1* and flanked by coding genes RA Guanyl Releasting Protein 1 (*RASGRP1*) and Thrombospondin 1 (*THBS1*), lead SNP rs1080066 was the most significant association (with precentral SA) detected across all of our phenotypes. Another four SNPs in very high LD with rs1080066 were associated with six additional SA and TH phenotypes. A sixth SNP, rs4923822 located ~22 Kb downstream and associated with transverse temporal SA, is in moderate LD (R^2~0.39 in Europeans) to the other five SNPs comprising this independent genomic locus (Supplementary Table 10).

Accross the six lead SNPs overlapping CCV sets include up to 14 SNPs, although this can be reduced to a minimum set of 10 that includes all six lead SNPs. This minimal set is indicated as influencing the expression of *THBS1*, and a non-coding RNA co-located with *THBS1* exons 18 and 19 (CTD-2033D15.1), in whole blood (Supplementary Table 11). These CCVs are located in a chromosomal region that interacts with downstream regions housing the promoters of *RP11-624L4.1* and *THBS1* in neural progenitor cells (Fig 4a; Supplementary Table 11). *THBS1* is also implicated as a candidate gene for two (lead SNPs rs3862145 [postcentral SA] and rs78502100 [supramarginal SA]) of the additional five independent genomic loci in this cytoband, through chromatin interactions between chromosomal regions housing these SNPs and the *THBS1* promoter in neural progenitor cells (Supplementary Table 11). *THBS1* has a role in synaptogenesis and the maintenance of synaptic integrity[95].

rs73313052, chromosome 14q23.1 (precuneus, pericalcarine and cuneus SA)
Lead SNP rs73313052 is one of five SNPs associated with six phenotypes at this independent genomic locus (Supplementary Table 10). These SNPs are located between the coding genes Dishevelled Binding Antagonist of Beta Catenin 1 (*DACT1*), with a role in synapse development[39], and Dishevelled Associated Activator of Morphogenesis 1 (*DAAM1*), recently shown to have a role in neuronal dendritic protrusion morphology[96]. There are two additional independent genomic loci located in this cytoband (Supplementary Table 10), one centromeric to rs73313052 and upstream of *DACT1* (most significant SNP rs160459, middle temporal TH) and one telomeric and at the 3' end of *DAAM1* (most significant SNP rs17834032, fusiform SA). Within each locus LD between SNPs is high (R^2 > 0.8), but there is no LD (r2 = 0) between SNPs comprising the different loci.

Across all three genomic loci there is evidence for an influence on *DAAM1*. The locus represented by rs73313052 is located in the *DAAM1* promoter region (upstream and including *DAAM1* intron 1; Fig 4e), with SNPs here acting as cortical eQTLs for *DAAM1* (e.g. rs73313052 FDR P_{CMC} = 0.049) and the nearby genes G Protein-Coupled Receptor 135 (*GPR135*) and Trans-L-3-Hydroxyproline Dehydratase (L3HYPDH). Both of the other loci in this cytoband show chromatin interactions from the regions of the lead SNPs to that of the *DAAM1* promoter in neural progenitor cells, with SNPs from the locus represented by rs17834032 also acting

as cortical eQTLs for *DAAM1*, *GPR135* and *L3HYPDH*. High LD proxies are located within an active transcription start site in adult cortex and fetal brain tissue (Fig. 4e).

rs910697 and rs2999158, chromosome 1p13.2
Lead SNPs rs910697 (lingual SA) and rs2999158 (pericalcarine SA) are in moderate LD with each other (R^2 = 0. 57), and comprise independent genomic locus 9 (Supplementary Table 10). These SNPs and their proxies are cortical eQTLs for Wnt pathway genes Suppression Of Tumorigenicity 7 Like (*ST7L*) and Wnt Family Member 2B (*WNT2BI:* FDR P_{CMC} = 0.009 for both SNPs for both genes), in addition to Capping Actin Protein Of Muscle Z-Line Subunit Alpha 1 (*CAPZA1*: $P_{GTEx\ Brain\ cortex}$ = 1.7 x 10^{-5}) and the non-coding RNA RP4-671G15.2 ($P_{GTEx\ Brain\ cortex}$ = 7.1 x 10^{-9}).

rs11161942 and rs1413536, chromosome 1p22.2
These two lead SNPs represent independent loci (R^2 = 0) associated with the SA of the posterior cingulate (rs11161942) and inferior parietal (rs1413536). A third independent locus within this chromosomal region (rs59373415) is associated with the SA of the precuneus (Supplementary Table 5). All are of interest due to their proximity to and predicted functional influence on the LIM Domain Only 4 (*LMO4*) gene (Supplementary Table 11). rs1413536 and 15 additional CCVs are cortical eQTLs for *LMO4* (FDR P_{CMC} = 0.009), with chromatin interactions between the region housing these SNPs and the *LMO4* promoter (Supplementary Table 11).

rs6505147, chromosome 17q11.2
Lead SNP rs6505147 is associated with the SA of the insula. Located within a large block of LD spanning ~680 Kb, this SNP is of interest due to its proximity to the serotonin transporter *SLC6A4*, located at the telomeric end of the LD block. Due to the extensive LD there are an additional 276 CCVs at this locus, hence determining a causal SNP at this locus will be challenging. rs6505147 and its proxies are eQTLs for numerous genes across the region in cortical tissue (Coronin *(CORO6)*, Slingshot Protein Phosphatase 2 *(SSH2)*, EF-Hand Calcium Binding Domain 5 *(EFCAB5)*, Bleomycin Hydrolase *(BLMH)*, Golgi SNAP Receptor Complex Member 1 *(GOSR1)*, SUZ12P1 PRS4 Recombination Region *(SUZ12P))*, with evidence for promoter activity particularly in the region of the *SSH2*, *EFCAB5* and *BLMH* promoters (Fig 4h). Evidence for a role for *SLC6A4* in insula SA is less convincing, with little evidence of promoter activity or transcription in adult cortex, fetal brain or astrocytes (Fig 4h). There are, however, chromatin interactions to the region of the *SLC6A4* promoter observed in neural progenitor cells, and rs6505147 and its proxies are eQTLs for *SLC6A4* in other tissue types (whole blood, esophagus, tibial nerve and testis, Supplementary Table 11). *SLC6A4* is an obvious candidate gene at this locus that has been extensively studied in relation to behavioural traits. Concomitant with a proposed role in mental health issues associated with stress, 5-HTT knockout mice show behavioural and cortical morphological abnormalities that alter their responses to trauma and stress[97]. However, a recent meta-analysis of 31 human studies, including 38 802 individuals of European ancestry, found no clear association between depression, stress and 5-HTTLPR[42]. As for all other loci, determining the candidate SNP and the gene it influences will require further bioinformatic and functional laboratory work.

Sulcal development
Positive genetic correlations between the SA of neighbouring regions may also be driven by the development of the sulcus, separating the regions. The pre- and post- central regions (also known as the primary motor and sensorimotor cortices, respectively) are consistently labelled across many cortical atlases as the regions directly anterior and posterior to the central sulcus (which appears early in development[98]). The SA of all four regions surrounding the calcarine sulcus (the pericalcarine, lingual, cuneus, and lateral occipital region) show positive genetic correlations. The same is also true for the SA of the insula and superior temporal gyri surrounding the lateral sulcus (or Sylvian fissure). These major, early forming sulci, show positive genetic correlations for SA, but not TH, of regions that directly surround them. These observations may imply that part of the genetic influences we observe to be underlying regional SA, may actually be driving the formation of the separating folds, or sulci, during fetal development.

The Desikan-Killiany atlas
The Desikan-Killiany atlas[12] used here to define the 34 regions of interest is one of many possible atlases. It is one of the coarser atlases, yielding larger, more consistent regions, defined by the common folding patterns visible on standard MRI. More recent efforts partitioning the cortex into 180 regions have used high-resolution multimodal assessments (MMPC)[99]. It is possible that positive correlations between adjacent structures may reflect suboptimal partitioning of the cortex by the Desikan-Killiany atlas into distinct functional brain regions; for example, we see a positive genetic correlation between the inferior parietal and the superior parietal gyri, whereas in the MMPC atlas, a portion of each of these two regions is included under the *intraparietal* labels. Portions of these genetically correlated regions may in future be re-assigned based on other advanced imaging data, such as multimodal myelin mapping, which may better define cortical cellular architecture.

Consortium Authors (#)

Alzheimer's Disease Neuroimaging Initiative (ADNI). Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, many investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators may be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

ADNI Infrastructure Investigators: Michael Weiner (UC San Francisco), Paul Aisen (University of Southern California), Ronald Petersen (Mayo Clinic, Rochester), Clifford R. Jack, Jr. (Mayo Clinic, Rochester), William Jagust (UC Berkeley), John Q. Trojanowki (U Pennsylvania), Arthur W. Toga (USC), Laurel Beckett (UC), Davis Robert C. Green (Brigham and Women's Hospital/Harvard Medical School), Andrew J. Saykin (Indiana University), John Morris (Washington University St. Louis), Leslie M. Shaw (University of Pennsylvania). *ADNI External Advisory Board (ESAB):* Zaven Khachaturian (Prevent Alzheimer's Disease 2020 (Chair)), Greg Sorensen (Siemens), Maria Carrillo (Alzheimer's Association), Lew Kuller (University of Pittsburgh), Marc Raichle (Washington University St. Louis), Steven Paul (Cornell University), Peter Davies (Albert Einstein College of Medicine of Yeshiva University), Howard Fillit (AD Drug Discovery Foundation), Franz Hefti (Acumen Pharmaceuticals), David Holtzman (Washington University St. Louis), M. Marcel Mesulam (Northwestern University), William Potter (National Institute of Mental Health), Peter Snyder (Brown University). *ADNI 3 Private Partner Scientific Board (PPSB):* Veronika Logovinsky,(Eli Lilly (Chair)). *Data and Publications Committee:* Robert C. Green (BWH/HMS (Chair)). *Resource Allocation Review Committee:* Tom Montine (University of Washington (Chair)). *Clinical Core Leaders:* Ronald Petersen (Mayo Clinic, Rochester (Core PI)), Paul Aisen (University of Southern California). *Clinical Informatics and Operations:* Gustavo Jimenez (USC), Michael Donohue (USC), Devon Gessert (USC), Kelly Harless (USC), Jennifer Salazar (USC), Yuliana Cabrera (USC), Sarah Walter (USC), Lindsey Hergesheimer (USC). *Biostatistics Core Leaders and Key Personnel:* Laurel Beckett (UC Davis (Core PI)), Danielle Harvey (UC Davis), Michael Donohue (UC San Diego). *MRI Core Leaders and Key Personnel:* Clifford R. Jack, Jr. (Mayo Clinic, Rochester (Core PI)), Matthew Bernstein (Mayo Clinic, Rochester), Nick Fox (University of London), Paul Thompson (UCLA School of Medicine), Norbert Schuff (UCSF MRI), Charles DeCArli (UC Davis), Bret Borowski (RT Mayo Clinic), Jeff Gunter (Mayo Clinic), Matt Senjem (Mayo Clinic), Prashanthi Vemuri (Mayo Clinic), David Jones (Mayo Clinic), Kejal Kantarci (Mayo Clinic), Chad Ward (Mayo Clinic). *PET Core Leaders and Key Personnel:* William Jagust (UC Berkeley (Core PI)), Robert A. Koeppe (University of Michigan), Norm Foster (University of Utah), Eric M. Reiman (Banner Alzheimer's Institute), Kewei Chen (Banner Alzheimer's Institute), Chet Mathis (University of Pittsburgh), Susan Landau (UC Berkeley). *Neuropathology Core Leaders:* John C. Morris (Washington University St. Louis), Nigel J. Cairns (Washington University St. Louis), Erin Franklin (Washington University St. Louis), Lisa Taylor-Reinwald (Washington University St. Louis – Past Investigator). *Biomarkers Core Leaders and Key Personnel:* Leslie M. Shaw (UPenn School of Medicine), John Q. Trojanowki (UPenn School of Medicine), Virginia Lee (UPenn School of Medicine), Magdalena Korecka (UPenn School of Medicine), Michal Figurski (UPenn School of Medicine). *Informatics Core Leaders and Key Personnel:* Arthur W. Toga (USC (Core PI)), Karen Crawford (USC), Scott Neu (USC). *Genetics Core Leaders and Key Personnel:* Andrew J. Saykin (Indiana University), Tatiana M. Foroud (Indiana University), Steven Potkin (UC Irvine), Li Shen (Indiana University), Kelley Faber (Indiana University), Sungeun Kim (Indiana University), Kwangsik Nho (Indiana University). *Initial Concept Planning & Development:* Michael W. Weiner (UC San Francisco), Lean Thal (UC San Diego), Zaven Khachaturian (Prevent Alzheimer's Disease 2020). *Early Project Proposal Development:* Leon Thal (UC San Diego), Neil Buckholtz (National Institute on Aging), Michael W. Weiner (UC San Francisco), Peter J. Snyder (Brown University), William Potter (National Institute of Mental Health), Steven Paul (Cornell University), Marilyn Albert (Johns Hopkins University), Richard Frank (Richard Frank Consulting), Zaven Khachaturian (Prevent Alzheimer's Disease 2020). *NIA:* John Hsiao (National Institute on Aging). *ADNI Investigators by Site: Oregon Health & Science University*: Joseph Quinn, Lisa C. Silbert, Betty Lind, Jeffrey A. Kaye – Past Investigator, Raina Carter – Past Investigator, Sara Dolen – Past Investigator. *University of Southern California:* Lon S. Schneider, Sonia Pawluczyk, Mauricio Becerra, Liberty Teodoro, Bryan M. Spann – Past Investigator. *University of California – San Diego:* James Brewer, Helen Vanderswag, Adam Fleisher – Past Investigator. *University of Michigan:* Jaimie Ziolkowski, Judith L. Heidebrink, Joanne L. Lord – Past Investigator. *Mayo Clinic, Rochester:* Ronald Petersen, Sara S. Mason, Colleen S. Albers, David Knopman, Kris Johnson – Past Investigator. *Baylor College of Medicine:* Javier Villanueva-Meyer, Valory Pavlik, Nathaniel Pacini, Ashley Lamb, Joseph S. Kass, Rachelle S. Doody – Past Investigator, Victoria Shibley – Past Investigator, Munir Chowdhury – Past Investigator, Susan Rountree – Past Investigator, Mimi Dang – Past Investigator. *Columbia University Medical Center:* Yaakov Stern, Lawrence S. Honig, Karen L. Bell, Randy Yeh. *Washington University, St. Louis:* Beau Ances, John C. Morris, David Winkfield, Maria Carroll, Angela Oliver, Mary L. Creech – Past Investigator, Mark A. Mintun – Past Investigator, Stacy Schneider – Past Investigator. *University of Alabama - Birmingham:* Daniel Marson, David Geldmacher, Marissa Natelson Love, Randall Griffith – Past Investigator, David Clark – Past Investigator, John Brockington – Past Investigator. *Mount Sinai School of Medicine:* Hillel Grossman, Effie Mitsis – Past Investigator. *Rush University Medical Center:* Raj C. Shah, Melissa Lamar, Patricia Samuels. *Wien Center:* Ranjan Duara, Maria T. Greig-Custo,

Rosemarie Rodriguez. *Johns Hopkins University:* Marilyn Albert, Chiadi Onyike, Daniel D'Agostino II, Stephanie Kielb – Past Investigator. *New York University:* Martin Sadowski, Mohammed O. Sheikh, Jamika Singleton-Garvin, Anaztasia Ulysse, Mrunalini Gaikwad. *Duke University Medical Center:* P. Murali Doraiswamy, Jeffrey R. Petrella, Olga James, Salvador Borges-Neto, Terence Z. Wong – Past Investigator, Edward Coleman – Past Investigator. *University of Pennsylvania:* Jason H. Karlawish, David A. Wolk, Sanjeev Vaishnavi, Christopher M. Clark – Past Investigator, Steven E. Arnold – Past Investigator. *University of Kentucky:* Charles D. Smith, Greg Jicha, Peter Hardy, Riham El Khouli, Elizabeth Oates, Gary Conrad. *University of Pittsburgh:* Oscar L. Lopez, MaryAnn Oakley, Donna M. Simpson. *University of Rochester Medical Center:* Anton P. Porsteinsson, Kim Martin, Nancy Kowalksi, Melanie Keltz, Bonnie S. Goldstein – Past Investigator, Kelly M. Makino – Past Investigator, M. Saleem Ismail – Past Investigator, Connie Brand – Past Investigator. *University of California Irvine IMIND:* Gaby Thai, Aimee Pierce, Beatriz Yanez, Elizabeth Sosa, Megan Witbracht. *University of Texas Southwestern Medical School:* Kyle Womack, Dana Mathews, Mary Quiceno. *Emory University:* Allan I. Levey, James J. Lah, Janet S. Cellar. *University of Kansas, Medical Center:* Jeffrey M. Burns, Russell H. Swerdlow, William M. Brooks. *University of California, Los Angeles:* Ellen Woo, Daniel H.S. Silverman, Edmond Teng, Sarah Kremen, Liana Apostolova – Past Investigator, Kathleen Tingus – Past Investigator, Po H. Lu – Past Investigator, George Bartzokis – Past Investigator. *Mayo Clinic, Jacksonville:* Neill R Graff-Radford (London), Francine Parfitt, Kim Poki-Walker. *Indiana University:* Martin R. Farlow, Ann Marie Hake, Brandy R. Matthews – Past Investigator, Jared R. Brosch, Scott Herring. *Yale University School of Medicine:* Christopher H. van Dyck, Richard E. Carson, Pradeep Varma. *McGill Univ., Montreal-Jewish General Hospital:* Howard Chertkow, Howard Bergman, Chris Hosein. *Sunnybrook Health Sciences, Ontario:* Sandra Black, Bojana Stefanovic, Chris (Chinthaka) Heyn. *U.B.C. Clinic for AD & Related Disorders:* Ging-Yuek Robin Hsiung, Benita Mudge, Vesna Sossi, Howard Feldman – Past Investigator, Michele Assaly – Past Investigator. *Cognitive Neurology - St. Joseph's, Ontario:* Elizabeth Finger, Stephen Pasternack, William Pavlosky, Irina Rachinsky – Past Investigator, Dick Drost – Past Investigator, Andrew Kertesz – Past Investigator. *Cleveland Clinic Lou Ruvo Center for Brain Health:* Charles Bernick, Donna Muni. *Northwestern University:* Marek-Marsel Mesulam, Emily Rogalski, Kristine Lipowski, Sandra Weintraub, Borna Bonakdarpour, Diana Kerwin – Past Investigator, Chuang-Kuo Wu,– Past Investigator, Nancy Johnson – Past Investigator. *Premiere Research Inst (Palm Beach Neurology):* Carl Sadowsky, Teresa Villena. *Georgetown University Medical Center:* Raymond Scott Turner, Kathleen Johnson, Brigid Reynolds. *Brigham and Women's Hospital*: Reisa A. Sperling, Keith A. Johnson, Gad A. Marshall. *Stanford University:* Jerome Yesavage, Joy L. Taylor, Steven Chao, Barton Lane – Past Investigator, Allyson Rosen – Past Investigator, Jared Tinklenberg – Past Investigator. *Banner Sun Health Research Institute:* Edward Zamrini, Christine M. Belden, Sherye A. Sirrel. *Boston University:* Neil Kowall, Ronald Killiany, Andrew E. Budson, Alexander Norbash – Past Investigator, Patricia Lynn Johnson – Past Investigator. *Howard University:* Thomas O. Obisesan, Ntekim E. Oyonumo, Joanne Allard, Olu Ogunlana. *Case Western Reserve University:* Alan Lerner, Paula Ogrocki, Curtis Tatsuoka, Parianne Fatica. *University of California, Davis – Sacramento:* Evan Fletcher, Pauline Maillard, John Olichney, Charles DeCarli, Owen Carmichael – Past Investigator. *Neurological Care of CNY:* Smita Kittur – Past Investigator. *Parkwood Institute:* Michael Borrie, T-Y Lee, Dr Rob Bartha. *University of Wisconsin:* Sterling Johnson, Sanjay Asthana, Cynthia M. Carlsson. *Banner Alzheimer's Institute:* Pierre Tariot, Anna Burke, Joel Hetelle, Kathryn DeMarco, Nadira Trncic – Past Investigator, Adam Fleisher – Past Investigator, Stephanie Reeder – Past Investigator. *Dent Neurologic Institute:* Vernice Bates, Horacio Capote, Michelle Rainka. *Ohio State University:* Douglas W. Scharre, Maria Kataki, Rawan Tarawneh. *Albany Medical College:* Earl A. Zimmerman, Dzintra Celmins, David Hart. *Hartford Hospital, Olin Neuropsychiatry Research Center:* Godfrey D. Pearlson, Karen Blank, Karen Anderson. *Dartmouth-Hitchcock Medical Center:* Laura A. Flashman, Marc Seltzer, Mary L. Hynes, Robert B. Santulli – Past Investigator. *Wake Forest University Health Sciences:* Kaycee M. Sink, Mia Yang, Akiva Mintz. *Rhode Island Hospital:* Brian R. Ott, Geoffrey Tremont, Lori A. Daiello. *Butler Hospital:* Courtney Bodge, Stephen Salloway, Paul Malloy, Stephen Correia, Athena Lee. *UC San Francisco:* Howard J. Rosen, Bruce L. Miller, David Perry. *Medical University South Carolina:* Jacobo Mintzer, Kenneth Spicer, David Bachman. *St. Joseph's Health Care:* Elizabeth Finger, Stephen Pasternak, Irina Rachinsky, John Rogers, Andrew Kertesz – Past Investigator, Dick Drost – Past Investigator. *Nathan Kline Institute:* Nunzio Pomara, Raymundo Hernando, Antero Sarrael. *University of Iowa College of Medicine:* Delwyn D. Miller, Karen Ekstam Smith, Hristina Koleva, Ki Won Nam, Hyungsub Shim, Susan K. Schultz – Past Investigator. *Cornell University:* Norman Relkin, Gloria Chiang, Michael Lin, Lisa Ravdin. *University of South Florida: USF Health Byrd Alzheimer's Institute:* Amanda Smith, Christi Leach, Balebail Ashok Raj – Past Investigator, Kristin Fargher – Past Investigator.

CHARGE Consortium: Edith Hofer (Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria), Gennady V. Roshchupkin (Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands), Hieab H. H. Adams (Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands), Maria J. Kno (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Honghuang Lin (Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA), Shuo Li (Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA), Habil Zare (Department of Computer Science,

Texas State University, San Marcos, Texas, USA.), Shahzad Ahmad (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Nicola J. Armstrong (Mathematics and Statistics, Murdoch University, Perth, Australia), Manon Bernard (Hospital for Sick Children, Toronto, Canada), Josh Bis (Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA), Nathan A. Gillespie (Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, VA, USA), Michelle Luciano (Centre for Cognitive Epidemiology and Cognitive Ageing, University of Edinburgh, Edinburgh, UK), Aniket Mishra (University of Bordeaux, Bordeaux Population Health Research Center, INSERM, Bordeaux, France), Markus Scholz (Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany), Alexander Teumer (Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany), Rui Xia (Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA), Xueqiu Jian (Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA), Thomas H. Mosley (Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA), Yasaman Saba (Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Graz, Austria), Lukas Pirpamer (Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria), Stephan Seiler (Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria), Uwe Völker (Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald), James T. Becker (Departments of Psychiatry, Neurology, and Psychology, University of Pittsburgh, Pittsburgh, PA, USA), Owen Carmichael (Pennington Biomedical Research Center, Baton Rouge, LA, USA), Jerome I. Rotter (Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute and Pediatrics at Harbor-UCLA Medical Center, Torrance, CA, USA), Bruce M. Psaty (Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, WA, USA), Oscar L. Lopez (Departments of Psychiatry, Neurology, and Psychology, University of Pittsburgh, Pittsburgh, PA, USA), Najaf Amin (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Sven J. van der Lee (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Qiong Yang (Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA), Claudia L. Satizabal (Department of Epidemiology and Biostatistics, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, USA), Jayandra J. Himali (Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA), Pauline Maillard (Imaging of Dementia and Aging (IDeA) Laboratory, Department of Neurology, University of California-Davis, Davis, CA, USA), Alexa S. Beiser (Department of Neurology, Boston University School of Medicine, Boston, MA, USA), Charles DeCarli (Department of Neurology and Center for Neuroscience, University of California at Davis, Sacramento, CA, USA), Sherif Karama (McGill University, Montreal Neurological Institute, Montreal, Canada), Lindsay Lewis (McGill University, Montreal Neurological Institute, Montreal, Canada), Mark Bastin (Centre for Cognitive Epidemiology and Cognitive Ageing, University of Edinburgh, Edinburgh, UK), Ian J. Deary (Centre for Cognitive Epidemiology and Cognitive Ageing, University of Edinburgh, Edinburgh, UK), Veronica Witte (Department of Neurology, Max Planck Institute of Cognitive and Brain Sciences, Leipzig, Germany), Frauke Beyer (Department of Neurology, Max Planck Institute of Cognitive and Brain Sciences, Leipzig, Germany), Markus Loeffler (Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany), Karen A. Mather (Centre for Healthy Brain Ageing,School of Psychiatry, University of New South Wales, Sydney, Australia), Peter R. Schofield (Neuroscience Research Australia, Sydney, Australia), Anbupalam Thalamuthu (Centre for Healthy Brain Ageing,School of Psychiatry, University of New South Wales, Sydney, Australia), John B. Kwok (School of Medical Sciences, University of New South Wales, Sydney, Australia), Margaret J. Wright (Queensland Brain Institute, The University of Queensland, St Lucia, QLD, Australia), David Ames (National Ageing Research Institute, Royal Melbourne Hospital, Victoria, Australia), Julian Trollor (Centre for Healthy Brain Ageing,School of Psychiatry, University of New South Wales, Sydney, Australia), Jiyang Jiang (Centre for Healthy Brain Ageing,School of Psychiatry, University of New South Wales, Sydney, Australia), Henry Brodaty (Dementia Centre for Research Collaboration, University of New South Wales, Sydney, NSW, Australia), Wei Wen (Centre for Healthy Brain Ageing,School of Psychiatry, University of New South Wales, Sydney, Australia), Meike W Vernooi (Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands), Albert Hofman (Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA), André G. Uitterlinden (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Wiro J. Niessen (Imaging Physics, Faculty of Applied Sciences, Delft University of Technology, The Netherlands), Katharina Wittfeld (German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Germany), Robin Bülow (Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany), Zdenka Pausova (Hospital for Sick Children, Toronto, Canada), Bruce Pike (Departments of Radiology and Neurology, University of Calgary, Calgary, Canada), Sophie Maingault (University of Bordeaux, Institut des Maladies Neurodégénratives, CNRS, Ubordeaux, Bordeaux, France), Bernard Mazoyer (University of Bordeaux, Institut des Maladies Neurodégénratives, CNRS, Ubordeaux, Bordeaux, France), Michael C. Neale (Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, VA, USA), Carol E. Franz (Department of Psychiatry, University of California San Diego, CA, USA), Michael J. Lyons (Department of Psychological and

Brain Sciences, Boston University, Boston, MA, USA), Matthew S. Panizzon (Department of Psychiatry, University of California San Diego, CA, USA), Mark Logue (National Center for PTSD at Boston VA Healthcare System, Boston, MA, USA), Perminder S. Sachdev (Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia), William S. Kremen (Department of Psychiatry, University of California San Diego, CA, USA), Joanna A. Wardlaw (Centre for Cognitive Epidemiology and Cognitive Ageing, University of Edinburgh, Edinburgh, UK), Arno Villringer (Department of Neurology, Max Planck Institute of Cognitive and Brain Sciences, Leipzig, Germany), Cornelia M. van Duijn (Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands), Hans Jörgen Grabe (Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Germany), WT. Longstreth Jr (Departments of Neurology and Epidemiology, University of Washington, Seattle, WA, USA), Myriam Fornage (Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA), Tomas Paus (Rotman Research Institute, Baycrest. Toronto, Canada), Stephanie Debette (University of Bordeaux, Bordeaux Population Health Research Center, INSERM, Bordeaux, France), M. Arfan Ikram (Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands), Helena Schmidt (Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Graz, Austria), Reinhold Schmidt (Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria), Sudha Seshadri (Department of Epidemiology and Biostatistics, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, USA)

EPIGEN Consortium: David B. Goldstein (The Centre for Genomics and Population Genetics, Duke University Institute for Genome Sciences and Policy, Durham, North Carolina, USA), Erin L. Heinzen (The Centre for Genomics and Population Genetics, Duke University Institute for Genome Sciences and Policy, Durham, North Carolina, USA), Kevin Shianna (The Centre for Genomics and Population Genetics, Duke University Institute for Genome Sciences and Policy, Durham, North Carolina, USA), Rodney Radtke (Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA) and Ruth Ottmann (Departments of Epidemiology, Neurology, and the G.H. Sergievsky Center, Columbia University, New York, NY).

IMAGEN Consortium: Dr. Eric Artiges (INSERM), Semiha Aydin (Physikalisch-Technische Bundesanstalt), Prof. Dr. Dr. Tobias Banaschewski (Central Institute of Mental Health), Alexis Barbot (Commissariat à l'Energie Atomique), Prof. Dr. Gareth Barker (King's College London), Andreas Becker (Georg-August-Universität Göttingen), Pauline Bezivin-Frere (INSERM), Dr. Francesca Biondo (King's College London), Dr. Arun Bokde (Trinity College Dublin), Uli Bromberg (University of Hamburg), Dr. Ruediger Bruehl, Prof. Dr. Christian Büchel (University of Hamburg), Dr. Congying Chu (King's College London), Dr. Patricia Conrod (King's College London), Laura Daedelow (Charité Universitätsmedizin Berlin), Dr. Jeffrey Dalley (Cambridge University), Dr. Sylvane Desrivieres (King's College London), Eoin Dooley (Trinity College Dublin), Irina Filippi (INSERM), Dr Ariane Fillmer (Physikalisch-Technische Bundesanstalt), Prof. Dr. Herta Flor (Central Institute of Mental Health), Juliane Fröhner (Technische Universität Dresden), Vincent Frouin (Commissariat à l'Energie Atomique), Dr. Hugh Garavan (University of Vermont), Prof. Penny Gowland (University of Nottingham), Yvonne Grimmer (Central Institute of Mental Health), Prof. Dr. Andreas Heinz (Charité Universitätsmedizin Berlin), Dr. Sarah Hohmann (Central Institute of Mental Health), Albrecht Ihlenfeld (Physikalisch-Technische Bundesanstalt), Alex Ing (King's College London), Corinna Isensee (University Medical Center Göttingen), Dr. Bernd Ittermann (Physikalisch-Technische Bundesanstalt), Dr. Tianye Jia (King's College London), Dr. Hervé Lemaitre (INSERM), Emma Lethbridge (University of Nottingham), Prof. Dr. Jean-Luc Martinot (INSERM), Sabina Millenet (Central Institute of Mental Health), Sarah Miller (Charité Universitätsmedizin Berlin), Ruben Miranda (INSERM), PD Dr. Frauke Nees (Central Institute of Mental Health), Dr. Marie-Laure Paillere (INSERM), Dimitri Papadopoulos (INSERM), Prof. Dr. Tomáš Paus (Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital and Departments of Psychology and Psychatry, University of Toronto), Dr. Zdenka Pausova (University of Toronto), Dr. Dr. Jani Pentilla (INSERM), Dr. Jean-Baptiste Poline (Commissariat à l'Energie Atomique), Prof. Dr. Luise Poustka (University Medical Center Göttingen), Dr. Erin Burke Quinlan (King's College London), Dr. Michael Rapp (Charité Universitätsmedizin Berlin), Prof. Dr. Trevor Robbins (Cambridge University), Dr. Gabriel Robert (King's College London), John Rogers (Delosis), Dr. Barbara Ruggeri (King's College London), Prof. Dr. Gunter Schumann (King's College London), Prof. Dr. Michael Smolka (Technische Universität Dresden), Argyris Stringaris (National Institute of Mental Health), Betteke van Noort (Charité Universitätsmedizin Berlin), Dr. Henrik Walter (Charité Universitätsmedizin Berlin), Dr. Robert Whelan (Trinity College Dublin), Prof. Dr. Steve Williams (King's College London).

Parkinson's Progression Markers Initiative (PPMI): Data used in preparing this article were obtained from the PPMI database (http://www.ppmi-info.org/). As such, many investigators within the PPMI contributed to the design and implementation of PPMI and/or provided data but did not participate in analysis or writing of this report. A complete listing of PPMI investigators may be found at: http://www.ppmi-info.org/authorslist/. Kenneth Marek (Institute for Neurodegenerative Disorders, New Haven), Danna Jennings (Institute for Neurodegenerative Disorders, New Haven), Shirley Lasch (Institute for Neurodegenerative Disorders, New

Haven), Caroline Tanner (University of California, San Francisco), Tanya Simuni (Northwestern University, Chicago), Christopher Coffey (University of Iowa, Iowa City), Karl Kieburtz (Clinical Trials Coordination Center, University of Rochester), Renee Wilson (Clinical Trials Coordination Center, University of Rochester), Werner Poewe (Innsbruck Medical University, Innsbruck), Brit Mollenhauer (Paracelsus-Elena Klinik, Kassel), Douglas Galasko (University of California, San Diego), Tatiana Foroud (Indiana University, Indianapolis), Todd Sherer (The Michael J. Fox Foundation for Parkinson's Research, New York), Sohini Chowdhury (The Michael J. Fox Foundation for Parkinson's Research, New York), Mark Frasier (The Michael J. Fox Foundation for Parkinson's Research, New York), Catherine Kopil (The Michael J. Fox Foundation for Parkinson's Research, New York), Vanessa Arnedo (The Michael J. Fox Foundation for Parkinson's Research, New York), Alice Rudolph (Clinical Trials Coordination Center, University of Rochester), Cynthia Casaceli (Clinical Trials Coordination Center, University of Rochester), John Seibyl (Institute for Neurodegenerative Disorders, New Haven), Susan Mendick (Institute for Neurodegenerative Disorders, New Haven), Norbert Schuff (University of California, San Francisco), Chelsea Caspell (University of Iowa, Iowa City), Liz Uribe (University of Iowa, Iowa City), Eric Foster (University of Iowa, Iowa City), Katherine Gloer (University of Iowa, Iowa City), Jon Yankey (University of Iowa, Iowa City), Arthur Toga (Laboratory of Neuroimaging (LONI), University of Southern California), Karen Crawford (Laboratory of Neuroimaging (LONI), University of Southern California), Paola Casalin (BioRep, Milan), Giulia Malferrari (BioRep, Milan), Andrew Singleton (National Institute on Aging, NIH, Bethesda), Keith A. Hawkins (Yale University, New Haven), David Russell (Institute for Neurodegenerative Disorders, New Haven), Stewart Factor (Emory University of Medicine, Atlanta), Penelope Hogarth (Oregon Health and Science University, Portland), David Standaert (University of Alabama at Birmingham, Birmingham), Robert Hauser (University of South Florida, Tampa), Joseph Jankovic (Baylor College of Medicine, Houston), Matthew Stern (University of Pennsylvania, Philadelphia), Lama Chahine (University of Pennsylvania, Philadelphia), James Leverenz (University of Washington, Seattle), Samuel Frank (Boston University, Boston), Irene Richard (University of Rochester, Rochester), Klaus Seppi (Innsbruck Medical University, Innsbruck), Holly Shill (Banner Research Institute, Sun City), Hubert Fernandez (Cleveland Clinic, Cleveland), Daniela Berg (University of Tuebingen, Tuebingen), Isabel Wurster (University of Tuebingen, Tuebingen), Zoltan Mari (Johns Hopkins University, Baltimore), David Brooks (Imperial College of London, London), Nicola Pavese (Imperial College of London, London), Paolo Barone (University of Salerno, Salerno), Stuart Isaacson (Parkinson's Disease and Movement Disorders Center, Boca Raton), Alberto Espay (University of Cincinnati, Cincinnati), Dominic Rowe (Macquarie University, Sydney), Melanie Brandabur (The Parkinson's Institute, Sunnyvale), James Tetrud (The Parkinson's Institute, Sunnyvale), Grace Liang (The Parkinson's Institute, Sunnyvale), Alex Iranzo (Hospital Clinic of Barcelona, Barcelona), Eduardo Tolosa (Hospital Clinic of Barcelona, Barcelona), Shu-Ching Hu (University of Washington, Seattle), Gretchen Todd (University of Washington, Seattle), Laura Leary (Institute for Neurodegenerative Disorders, New Haven), Cheryl Riordan (Institute for Neurodegenerative Disorders, New Haven), Linda Rees (The Parkinson's Institute, Sunnyvale), Alicia Portillo (Oregon Health and Science University, Portland), Art Lenahan (Oregon Health and Science University, Portland), Karen Williams (Northwestern University, Chicago), Stephanie Guthrie (University of Alabama at Birmingham, Birmingham), Ashlee Rawlins (University of Alabama at Birmingham, Birmingham), Sherry Harlan (University of South Florida, Tampa), Christine Hunter (Baylor College of Medicine, Houston), Baochan Tran (University of Pennsylvania, Philadelphia), Abigail Darin (University of Pennsylvania, Philadelphia), Carly Linder (University of Pennsylvania, Philadelphia), Marne Baca (University of Washington, Seattle), Heli Venkov (University of Washington, Seattle), Cathi-Ann Thomas (Boston University, Boston), Raymond James (Boston University, Boston), Cheryl Deeley (University of Rochester, Rochester), Courtney Bishop (University of Rochester, Rochester), Fabienne Sprenger (Innsbruck Medical University, Innsbruck), Diana Willeke (Paracelsus-Elena Klinik, Kassel), Sanja Obradov (Banner Research Institute, Sun City), Jennifer Mule (Cleveland Clinic, Cleveland), Nancy Monahan (Cleveland Clinic, Cleveland), Katharina Gauss (University of Tuebingen, Tuebingen), Deborah Fontaine (University of California, San Diego), Christina Gigliotti (University of California, San Diego), Arita McCoy (Johns Hopkins University, Baltimore), Becky Dunlop (Johns Hopkins University, Baltimore), Bina Shah (Imperial College of London, London), Susan Ainscough (University of Salerno, Salerno), Angela James (Parkinson's Disease and Movement Disorders Center, Boca Raton), Rebecca Silverstein (Parkinson's Disease and Movement Disorders Center, Boca Raton), Kristy Espay (University of Cincinnati, Cincinnati), Madelaine Ranola (Macquarie University, Sydney), Thomas Comery (Pfizer, Inc., Groton), Jesse Cedarbaum (Biogen Idec, Cambridge), Bernard Ravina (Biogen Idec, Cambridge), Igor D. Grachev (GE Healthcare, Princeton), Jordan S. Dubow (AbbVie, Abbot Park), Michael Ahlijanian (Bristol-Myers Squibb Company), Holly Soares (Bristol-Myers Squibb Company), Suzanne Ostrowizki (F.Hoffmann La-Roche, Basel), Paulo Fontoura (F.Hoffmann La-Roche, Basel), Alison Chalker (Merck & Co., North Wales), David L. Hewitt (Merck & Co., North Wales), Marcel van der Brug (Genentech, Inc., South San Francisco), Alastair D. Reith (GlaxoSmithKline, Stevenage), Peggy Taylor (Covance, Dedham), Jan Egebjerg (H. Lundbeck), Mark Minton (Avid Radiopharmaceuticals, Philadelphia), Andrew Siderowf (Avid Radiopharmaceuticals, Philadelphia), Pierandrea Muglia (UCB Pharma S.A., Brussels), Robert Umek (Meso Scale Discovery), Ana Catafau (Meso Scale Discovery), Vera Kiyasova (Servier), Barbara Saba (Servier).

SYS Consortium: Tomáš Paus MD PhD (Bloorview Research Institute, University of Toronto, Canada), Zdenka Pausova, MD (The Hospital for Sick Children, University of Toronto, Canada), G. Bruce Pike PhD (Department of Radiology, University of Calgary, Canada), Louis Richer PhD (Department of Health Sciences, University of Quebec in Chicoutimi, Canada), Gabriel Leonard PhD (Montreal Neurological Institute, McGill University, Canada), Michel Perron PhD (CEGEP Jonquiere, Canada), Suzanne Veillette PhD (CEGEP Jonquiere, Canada) and Manon Bernard BComp(The Hospital for Sick Children, University of Toronto, Canada).

Additional cohort information

ADNI

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative database. The ADNI was launched in 2003 as a 5-year public–private partnership to assess and optimize biomarkers for clinical trials in Alzheimer's disease. The initial sample included older adults who were cognitive normal (CN) as well as meeting criteria for MCI and clinical AD. In 2011, ADNI-2 began to recruit an additional CN group as well as individuals with significant memory concerns (SMC), early MCI and late MCI,and AD. . These subjects, and others carried forward from ADNI-1, were scanned with an updated neuroimaging protocol. Participants were recruited from over 60 sites across the U.S. and Canada. For up-to-date information, please see www.adni-info.org.

ALSPAC

Pregnant women resident in Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992 were invited to take part in the study. The initial number of pregnancies enrolled is 14,541 (for these at least one questionnaire has been returned or a "Children in Focus" clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total of 14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally. As a result, when considering variables collected from the age of seven onwards (and potentially abstracted from obstetric notes) there are data available for more than the 14,541 pregnancies mentioned above. The number of new pregnancies not in the initial sample (known as Phase I enrolment) that are currently represented on the built files and reflecting enrolment status at the age of 18 is 706 (452 and 254 recruited during Phases II and III respectively), resulting in an additional 713 children being enrolled. The phases of enrolment are described in more detail in the cohort profile paper (see footnote 4 below). The total sample size for analyses using any data collected after the age of seven is therefore 15,247 pregnancies, resulting in 15,458 fetuses. Of this total sample of 15,458 fetuses, 14,775 were live births and 14,701 were alive at 1 year of age. A 10% sample of the ALSPAC cohort, known as the Children in Focus (CiF) group, attended clinics at the University of Bristol at various time intervals between 4 to 61 months of age. The CiF group were chosen at random from the last 6 months of ALSPAC births (1432 families attended at least one clinic). Excluded were those mothers who had moved out of the area or were lost to follow-up, and those partaking in another study of infant development in Avon. The data used in the present study were collected from 391 males and further description of this subset and the variables used in this study are provided in Supplementary Tables 2-4.

The study website contains details of all the data that is available through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/).

Further information can be found in the following papers:

Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G. Cohort Profile: The 'Children of the 90s'; the index offspring of The Avon Longitudinal Study of Parents and Children (ALSPAC). International Journal of Epidemiology 2013; 42: 111-127;

Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson SM, Lawlor DA. Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. International Journal of Epidemiology 2013; 42:97-110;

References

87 McClard, C. K. *et al.* POU6f1 Mediates Neuropeptide-Dependent Plasticity in the Adult Brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **38**, 1443-1461, doi:10.1523/jneurosci.1641-17.2017 (2018).

88 Dobson-Stone, C. *et al.* GSK3B and MAPT polymorphisms are associated with grey matter and intracranial volume in healthy individuals. *PloS one* **8**, e71750, doi:10.1371/journal.pone.0071750 (2013).

89 Arbogast, T. *et al.* Mouse models of 17q21.31 microdeletion and microduplication syndromes highlight the importance of Kansl1 for cognition. *PLoS genetics* **13**, e1006886, doi:10.1371/journal.pgen.1006886 (2017).

90 Shi, C., Viccaro, K., Lee, H. G. & Shah, K. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models. *Journal of cell science* **129**, 1815-1830, doi:10.1242/jcs.185009 (2016).
91 Gilmore, E. C. & Walsh, C. A. Genetic causes of microcephaly and lessons for neuronal development. *Wiley interdisciplinary reviews. Developmental biology* **2**, 461-478, doi:10.1002/wdev.89 (2013).
92 Pankratova, S. *et al.* The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival. *Theranostics* **8**, 3977-3990, doi:10.7150/thno.22274 (2018).
93 Lee, H. F., Chi, C. S., Tsai, C. R., Chen, H. C. & Lee, I. C. Prenatal brain disruption in isolated sulfite oxidase deficiency. *Orphanet journal of rare diseases* **12**, 115, doi:10.1186/s13023-017-0668-3 (2017).
94 Zhou, Y. *et al.* Interactome analysis reveals ZNF804A, a schizophrenia risk gene, as a novel component of protein translational machinery critical for embryonic neurodevelopment. *Mol Psychiatry* **23**, 952-962, doi:10.1038/mp.2017.166 (2018).
95 Jayakumar, A. R. *et al.* Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies. *Journal of neurochemistry* **131**, 333-347, doi:10.1111/jnc.12810 (2014).
96 Kawabata Galbraith, K. *et al.* MTSS1 Regulation of Actin-Nucleating Formin DAAM1 in Dendritic Filopodia Determines Final Dendritic Configuration of Purkinje Cells. *Cell reports* **24**, 95-106.e109, doi:10.1016/j.celrep.2018.06.013 (2018).
97 Wellman, C. L. *et al.* Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **27**, 684-691, doi:10.1523/jneurosci.4595-06.2007 (2007).
98 Bruyn, G. W. Atlas of the cerebral sulci. *Clinical Neurology and Neurosurgery* **93**, 93, doi:10.1016/0303-8467(91)90043-O (1991).
99 Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex. *Nature* **536**, 171 (2016).

Acknowledgements
ENIGMA: The study was supported in part by grant U54 EB020403 from the NIH Big Data to Knowledge (BD2K) Initiative, a cross-NIH partnership. Additional support was provided by R01MH116147, P41 EB015922, RF1AG051710, RF1 AG041915 (to P.T.), by P01 AG026572, R01 AG059874 and by R01 MH117601 (to N.J. and L.S.). S.E.M. was funded by an NHMRC Senior Research Fellowship (APP1103623). L.C.-C. was supported by a QIMR Berghofer Fellowship.

1000BRAINS: Is a population-based cohort based on the Heinz-Nixdorf Recall Study and is supported in part by the German National Cohort. We thank the Heinz Nixdorf Foundation (Germany) for their generous support in terms of the Heinz Nixdorf Study. The HNR study is also supported by the German Ministry of Education and Science (FKZ 01EG940), and the German Research Council (DFG, ER 155/6-1). The authors are supported by the Initiative and Networking Fund of the Helmholtz Association (Svenja Caspers) and the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreements 720270 (Human Brain Project SGA1; Sven Cichon) and 785907 (Human Brain Project SGA2; Svenja Caspers, Sven Cichon). This work was further supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of the e:Med Program (grant 01ZX1314A; Sven Cichon), and by the Swiss National Science Foundation (SNSF, grant 156791; Sven Cichon).

ADNI1 and ADNI2GO: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Samples from the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. Additional support for data analysis was provided by NLM R01 LM012535 and NIA R03 AG054936 (to K.N.).

ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and they will serve as guarantors for the contents of this paper. *A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf)*. ALSPAC neuroimaging data was specifically funded by RO1 MH085772 (Axon, Testosterone and Mental Health during Adolescence; PI: T. Paus). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We would like to acknowledge the help of Lara B Clauss during the quality control process of the ALSPAC neuroimaging data.

BETULA: This work was supported by a Wallenberg Scholar grant from the Knut and Alice Wallenberg (KAW) Foundation and a grant from Torsten and Ragnar Söderbergs Foundation to LN, a grant from HelseVest RHF

(Grant 911554) to SLH, grants from the Bergen Research Foundation and the University of Bergen to SLH, grants from the Dr Einar Martens Fund and the K.G. Jebsen Foundation to SLH and VMS, the Research Council of Norway to TE (Grant 177458/V 50) and LTW (Grant 204966/F 20). We thank the Centre for Advanced Study (CAS) at the Norwegian Academy of Science and Letters in Oslo for hosting collaborative projects and workshops between Norway and Sweden in 2011–2012. Image analyses were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at HPC2N in Umeå.

BIG: The Brain Imaging Genetics (BIG) database was established in Nijmegen, the Netherlands in 2007. This resource is now part of Cognomics, a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Center, and the Max Planck Institute for Psycholinguistics. The present study includes two subsamples of BIG, from successive waves of genotyping on Affymetrix (BIG-Affy) and PsychChip (BIG-PsychChip) arrays. Analyses for this project were carried out on the Dutch national e-infrastructure with the support of SURF Cooperative. Nijmegen's BIG resource is part of Cognomics, a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Center, and the Max Planck Institute for Psycholinguistics (funded by the Max Planck Society). Support for the Cognomics Initiative, including phenotyping and genotyping of BIG cohorts, comes from funds of the participating departments and centres and from external national grants, i.e. the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland, and the Netherlands Organisation for Scientific Research (NWO), including the NWO Brain & Cognition Excellence Program (grant 433-09-229) and the Vici Innovation Program (grant 016-130-669 to BF). Additional support was received from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreements n◦ 602805 (Aggressotype), n◦ 602450 (IMAGEMEND), and n◦ 278948 (TACTICS) as well as from the European Community's Horizon 2020 Programme (H2020/2014–2020) under grant agreements n◦ 643051 (MiND) and n◦ 667302 (CoCA) and and from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking (H2020/EFPIA) under grant agreement no. 115916 (PRISM). The work was also supported by grants for the ENIGMA Consortium (Foundation for the National Institutes of Health (NIH); grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership.

BONN: The authors would like to thank (in alphabetical order) Marcel Bartling, Ulrike Broicher, Laura Ehrmantraut, Anna Maaser, Bettina Mahlow, Stephanie Mentges, Karolina Raczka, Laura Schinabeck, and Peter Trautner for their support and help. The study was partly funded by the Frankfurt Institute for Risk Management and Regulation (FIRM) and BW was supported by a Heisenberg Grant of the German Research Foundation ((Deutsche Forschungsgemeinschaft (DFG)), WE 4427(3-2)).

BrainScale: This work was supported by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO 51.02.061 to H.H., NWO 51.02.062 to D.B., NWO-NIHC Programs of excellence 433-09-220 to H.H., NWO-MagW 480-04-004 to D.B., and NWO/SPI 56-464-14192 to D.B.); FP7 Ideas: European Research Council (ERC-230374 to D.B.); and Universiteit Utrecht (High Potential Grant to H.H.).

CARDIFF: We are grateful to all researchers within Cardiff University who contributed to the MBBrains panel and to NCMH for their support with genotyping. NCMH supported genotyping.

CHARGE: Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute grant HL105756 and for the neuroCHARGE phenotype working group through the National Institute on Aging grant AG033193. *Atherosclerosis Risk in Communities Study (ARIC):* The Atherosclerosis Risk in Communities study was performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HSN268201100006C, HSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health (NIH) contract HHSN268200625226C. Infrastructure was partly supported by grant No. UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This project was partially supported by National Institutes of Health R01 grants HL084099 and NS087541 to MF. *Austrian Stroke Prevention Family (ASPS) / Austrian Stroke Prevention Family Study:* The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The Medical University of Graz and the Steiermärkische Krankenanstaltengesellschaft support the databank of the ASPS/ASPS-Fam. The research reported in this article was funded by the Austrian Science Fund (FWF) grant numbers PI904, P20545-P05 and P13180 and supported by the Austrian National Bank Anniversary Fund, P15435 and the Austrian Ministry of Science under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu.

Cardiovascular Health Study (CHS): This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and R01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG15928, and R01AG033193 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. *Erasmus Rucphen Family Study (ERF):* Erasmus Rucphen Family (ERF) was supported by the Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO). ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (No. QLG2-CT-2002-01254) as well as FP7 project EUROHEADPAIN (nr602633). High-throughput analysis of the ERF data was supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). High throughput metabolomics measurements of the ERF study has been supported by BBMRI-NL (Biobanking and Biomolecular Resources Research Infrastructure Netherlands). *Framingham Heart Study (FHS):* This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195 and No. HHSN268201500001I) and its contract with Affymetrix, Inc. for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported by grants from the National Institute of Aging (R01s AG033040, AG033193, AG054076, AG049607, AG008122, AG016495; and U01-AG049505) and the National Institute of Neurological Disorders and Stroke (R01-NS017950). We would like to thank the dedication of the Framingham Study participants, as well as the Framingham Study team, especially investigators and staff from the Neurology group, for their contributions to data collection. Dr. DeCarli is supported by the Alzheimer's Disease Center (P30 AG 010129). The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. *Lothian Birth Cohort 1936 (LBC1936):* This project is funded by the Age UK's Disconnected Mind programme (http://www.disconnectedmind.ed.ac.uk) and also by Research Into Ageing (Refs. 251 and 285). The whole genome association part of the study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC; Ref. BB/F019394/1). Analysis of the brain images was funded by the Medical Research Council Grants G1001401 and 8200. The imaging was performed at the Brain Research Imaging Centre, The University of Edinburgh (http://www.bric.ed.ac.uk), a centre in the SINAPSE Collaboration (http://www.sinapse.ac.uk). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (http://www.ccace.ed.ac.uk), part of the cross council Lifelong Health and Wellbeing Initiative (Ref. G0700704/84698). Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC), Medical Research Council (MRC) and Scottish Funding Council through the SINAPSE Collaboration is gratefully acknowledged. We thank the LBC1936 participants and research team members. We also thank the nurses and staff at the Wellcome Trust Clinical Research Facility (http://www.wtcrf.ed.ac.uk), where subjects were tested and the genotyping was performed. *LIFE-Adult:* LIFE-Adult is funded by the Leipzig Research Center for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative. This work was also funded by the Deutsche Forschungsgemeinschaft (Grant Number: CRC 1052 "Obesity mechanisms" project A1 to AV) and by the Max Planck Society. *Sydney Memory and Ageing Study (MAS):* MAS is funded by the Australian National Health and Medical Research Council (NHMRC)/Australian Research Council Strategic Award (Grant 401162), NHMRC Project grant 1405325. We would like to gratefully acknowledge and thank the Sydney MAS participants and supporters and the Sydney MAS Research Team. *Older Australian Twin Study (OATS):* OATS is funded by the Australian National Health and Medical Research Council (NHMRC)/Australian Research Council Strategic Award (Grant 401162) , NHMRC Program Grants (350833, 568969, 109308) We would like thank and gratefully acknowledge the OATS participants, their supporters and the OATS Research Team. *Rotterdam Study (RSI, RSII, RSIII):* The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education,

Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, and Carolina Medina-Gomez, for their help in creating the GWAS database, and Karol Estrada, Yurii Aulchenko, and Carolina Medina-Gomez, for the creation and analysis of imputed data. This work has been performed as part of the CoSTREAM project (www.costream.eu) and has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667375. *Study of Health in Pomerania (SHIP) / Study of Health in Pomerania Trend (SHIP- Trend):* SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. Whole-body MR imaging was supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. *Saguenay Youth Study (SYS):* The Saguenay Youth Study has been funded by the Canadian Institutes of Health Research (TP, ZP), Heart and Stroke Foundation of Canada (ZP), and the Canadian Foundation for Innovation (ZP). We thank all families who took part in the Saguenay Youth Study. SYS is supported by the Canadian Institutes of Health Research: NET54015, NRF86678, TMH109788. *Three-City Dijon (3C-Dijon):* The Three City (3C) Study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Bordeaux, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l'Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme "Cohortes et collections de données biologiques." Christophe Tzourio and Stéphanie Debette have received investigator-initiated research funding from the French National Research Agency (ANR) and from the Fondation Leducq. Stéphanie Debette is supported by a starting grant from the European Research Council (SEGWAY), a grant from the Joint Programme of Neurodegenerative Disease research (BRIDGET), and the Initiative of Excellence of Bordeaux University. We thank Dr. Anne Boland (CNG) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille, the labex DISTALZ and the Centre National de Génotypage. *Vietnam Era Twin Study of Aging (VETSA):* United States National Institute of Health VA San Diego Center of Excellence for Stress and Mental Health R00DA023549; DA-18673; NIA R01 AG018384; R01 AG018386; R01 AG022381; R01 AG022982; R01 DA025109 05; R01 HD050735; K08 AG047903; R03 AG 046413; U54 EB020403; and R01 HD050735-01A2

CLING: The GIG (Genomic Imaging Göttingen) sample was established at the Center for Translational Research in Systems Neuroscience and Psychiatry (Head: Prof. Dr. O. Gruber) at Göttingen University. We thank Maria Keil, Esther Diekhof, Tobias Melcher and Ilona Henseler for assistance in data acquisition. We are grateful to all persons who kindly participated in the GIG study.

DNS: We thank the Duke Neurogenetics Study participants and the staff of the Laboratory of NeuroGenetics. The Duke Neurogenetics Study received support from Duke University as well as US-National Institutes of Health grants R01DA033369 and R01DA031579.

EPIGEN: Work from the London Cohort was supported by research grants from the Wellcome Trust (grant 084730 to S.M.S.), University College London (UCL)/University College London Hospitals (UCLH) NIHR Biomedical Research Centre/Specialist Biomedical Research Centres (CBRC/SBRC) (grant 114 to S.M.S.), the Comprehensive Local Research Network (CLRN) Flexibility and Sustainability Funding (FSF) (grant CEL1300 to S.M.S.), The Big Lottery Fund, the Wolfson Trust and the Epilepsy Society. This work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme.

FBIRN: We are thankful to Mrs. Liv McMillan, BS for overall study coordination, Harry Mangalam, PhD, Joseph Farran, BS, and Adam Brenner, BS, for administering the University of California, Irvine High-Performance Computing cluster, and to the research subjects for their participation. This work was supported by the National Center for Research Resources at the National Institutes of Health [grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center)], the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR000153, and the National Institutes of Health through 5R01MH094524, and P20GM103472.

FOR2107: This work was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2 to UD; JA1890/7-1, JA1890/7-2 to AJ; KI 588/14-1, KI 588/14-2 to TK; KR 3822/7-1, KR 3822/7-2 to AK; NO246/10-1, NO246/10-2 to MMN).

Frontal-temporal dementia GWAS (utlised to calculate the genetic correlations). We acknowledge the investigators of the original study (Ferrari et al.[73]): Raffaele Ferrari, Dena G Hernandez, Michael A Nalls, Jonathan D Rohrer, Adaikalavan Ramasamy, John BJ Kwok, Carol Dobson-Stone, William S Brooks, Peter R Schofield, Glenda M Halliday, John R Hodges, Olivier Piguet, Lauren Bartley, Elizabeth Thompson, Eric Haan, Isabel Hernández, Agustín Ruiz, Mercè Boada, Barbara Borroni, Alessandro Padovani, Carlos Cruchaga, Nigel J Cairns, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Gianluigi Forloni, Diego Albani, Daniela Galimberti, Chiara Fenoglio, Maria Serpente, Elio Scarpini, Jordi Clarimón, Alberto Lleó, Rafael Blesa, Maria Landqvist Waldö, Karin Nilsson, Christer Nilsson, Ian RA Mackenzie, Ging-Yuek R Hsiung, David MA Mann, Jordan Grafman, Christopher M Morris, Johannes Attems, Ian G McKeith, Alan J Thomas, Pietro Pietrini, Edward D Huey, Eric M Wassermann, Atik Baborie, Evelyn Jaros, Michael C Tierney, Pau Pastor, Cristina Razquin, Sara Ortega-Cubero, Elena Alonso, Robert Perneczky, Janine Diehl- Schmid, Panagiotis Alexopoulos, Alexander Kurz, Innocenzo Rainero, Elisa Rubino, Lorenzo Pinessi, Ekaterina Rogaeva, Peter St George-Hyslop, Giacomina Rossi, Fabrizio Tagliavini, Giorgio Giaccone, James B Rowe, Johannes CM Schlachetzki, James Uphill, John Collinge, Simon Mead, Adrian Danek, Vivianna M Van Deerlin, Murray Grossman, John Q Trojanowski, Julie van der Zee, Marc Cruts, Christine Van Broeckhoven, Stefano F Cappa, Isabelle Leber, Didier Hannequin, Véronique Golfier, Martine Vercelletto, Alexis Brice, Benedetta Nacmias, Sandro Sorbi, Silvia Bagnoli, Irene Piaceri, Jørgen E Nielsen, Lena E Hjermind, Matthias Riemenschneider, Manuel Mayhaus, Bernd Ibach, Gilles Gasparoni, Sabrina Pichler, Wei Gu, Martin N Rossor, Nick C Fox, Jason D Warren, Maria Grazia Spillantini, Huw R Morris, Patrizia Rizzu, Peter Heutink, Julie S Snowden, Sara Rollinson, Anna Richardson, Alexander Gerhard, Amalia C Bruni, Raffaele Maletta, Francesca Frangipane, Chiara Cupidi, Livia Bernardi, Maria Anfossi, Maura Gallo, Maria Elena Conidi, Nicoletta Smirne, Rosa Rademakers, Matt Baker, Dennis W Dickson, Neill R Graff-Radford, Ronald C Petersen, David Knopman, Keith A Josephs, Bradley F Boeve, Joseph E Parisi, William W Seeley, Bruce L Miller, Anna M Karydas, Howard Rosen, John C van Swieten, Elise GP Dopper, Harro Seelaar, Yolande AL Pijnenburg, Philip Scheltens, Giancarlo Logroscino, Rosa Capozzo, Valeria Novelli, Annibale A Puca, Massimo Franceschi, Alfredo Postiglione, Graziella Milan, Paolo Sorrentino, Mark Kristiansen, Huei-Hsin Chiang, Caroline Graff, Florence Pasquier, Adeline Rollin, Vincent Deramecourt, Thibaud Lebouvier, Dimitrios Kapogiannis, Luigi Ferrucci, Stuart Pickering-Brown, Andrew B Singleton, John Hardy, Parastoo Momeni. Acknowledgement: Intramural funding from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA), the Wellcome/MRC Centre on Parkinson's disease, Alzheimer's Research UK (ARUK, Grant ARUK-PG2012-18) and by the office of the Dean of the School of Medicine, Department of Internal Medicine, at Texas Tech University Health Sciences Center. We thank Mike Hubank and Kerra Pearce at the Genomic core facility at the Institute of Child Health (ICH), University College of London (UCL), for assisting RF in performing Illumina genotyping experiments (FTD-GWAS genotyping). This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://biowulf.nih.gov). North American Brain Expression Consortium (NABEC) - The work performed by the North American Brain Expression Consortium (NABEC) was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, part of the US Department of Health and Human Services; project number ZIA AG000932-04. In addition this work was supported by a Research Grant from the Department of Defense, W81XWH-09-2-0128. UK Brain Expression Consortium (UKBEC) - This work performed by the UK Brain Expression Consortium (UKBEC) was supported by the MRC through the MRC Sudden Death Brain Bank (C.S.), by a Project Grant (G0901254 to J.H. and M.W.) and by a Fellowship award (G0802462 to M.R.). D.T. was supported by the King Faisal Specialist Hospital and Research Centre, Saudi Arabia. Computing facilities used at King's College London were supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. We would like to thank AROS Applied Biotechnology AS company laboratories and Affymetrix for their valuable input. RF's work is supported by Alzheimer's Society (grant number 284), UK; JBJK was supported by the National Health and Medical Resarch Council (NHMRC) Australia, Project Grants 510217 and 1005769; CDS was supported by NHMRC Project Grants 630428 and 1005769; PRS was supported by NHMRC Project Grants 510217 and 1005769 and

acknowledges that DNA samples were prepared by Genetic Repositories Australia, supported by NHMRC Enabling Grant 401184; GMH was supported by NHMRC Research Fellowship 630434, Project Grant 1029538, Program Grant 1037746; JRH was supported by the Australian Research Council Federation Fellowship, NHMRC Project Grant 1029538, NHMRC Program Grant 1037746; OP was supported by NHMRC Career Development Fellowship 1022684, Project Grant 1003139. IH, AR and MB acknowledge the patients and controls who participated in this project and the Trinitat Port-Carbó and her family who are supporting Fundació ACE research programs. CC was supported by Grant P30- NS069329-01 and acknowledges that the recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. LB and GB were supported by the Ricerca Corrente, Italian Ministry of Health; RG was supported by Fondazione CARIPLO 2009-2633, Ricerca Corrente, Italian Ministry of Health; GF was supported by Fondazione CARIPLO 2009-2633. ES was supported by the Italian Ministry of Health; CF was supported by Fondazione Cariplo; MS was supported from the Italian Ministry of Health (Ricerca Corrente); MLW was supported by Government funding of clinical research within NHS Sweden (ALF); KN was supported by Thure Carlsson Foundation; CN was supported by Swedish Alzheimer Fund. IRAM and GYRH were supported by CIHR (grant 74580) PARF (grant C06-01). JG was supported by the NINDS intramural research funds for FTD research. CMM was supported by Medical Research Council UK, Brains for Dementia Research, Alzheimer's Society, Alzheimer's Research UK, National Institutes for Health Research, Department of Health, Yvonne Mairy Bequest and acknowledges that tissue made available for this study was provided by the Newcastle Brain Tissue Resource, which was funded in part by grants G0400074 and G1100540 from the UK MRC, the Alzheimer's Research Trust and Alzheimer's Society through the Brains for Dementia Research Initiative and an NIHR Biomedical Research Centre Grant in Ageing and Health, and NIHR Biomedical Research Unit in Lewy Body Disorders. CMM was supported by the UK Department of Health and Medical Research Council and the Research was supported by the National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University and acknowledges that the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health; JA was supported by MRC, Dunhill Medical Trust, Alzheimer's Research UK; TDG was supported by Wellcome Trust Senior Clinical Fellow; IGM was supported by NIHR Biomedical Research Centre and Unit on Ageing Grants and acknowledges the National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health; AJT was supported by Medical Research Council, Alzheimer's Society, Alzheimer's Research UK, National Institutes for Health Research. EJ was supported by NIHR, Newcastle Biomedical Research Centre. PP, CR, SOC and EA were supported partially by FIMA (Foundation for Applied Medical Research); PP acknowledges Manuel Seijo-Martínez (Department of Neurology, Hospital do Salnés, Pontevedra, Spain), Ramon Rene, Jordi Gascon and Jaume Campdelacreu (Department of Neurology, Hospital de Bellvitge, Barcelona, Spain) for providing FTD DNA samples. RP, JDS, PA and AK were supported by German Federal Ministry of Education and Research (BMBF; grant number FKZ 01GI1007A – German FTLD consortium). IR was supported by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) of Italy. PStGH was supported by the Canadian Institutes of Health Research, Wellcome Trust, Ontario Research Fund. FT was supported by the Italian Ministry of Health (ricerca corrente) and MIUR grant RBAP11FRE9; GR and GG were supported by the Italian Ministry of Health (ricerca corrente). JBR was supported by Camrbidge NIHR Biomedical Research Centre and Wellcome Trust (088324). JU, JC, SM were supported by the MRC Prion Unit core funding and acknowledge MRC UK, UCLH Biomedical Research Centre, Queen Square Dementia BRU; SM acknowledges the work of John Beck, Tracy Campbell, Gary Adamson, Ron Druyeh, Jessica Lowe, Mark Poulter. AD acknowledges the work of Benedikt Bader and of Manuela Neumann, Sigrun Roeber, Thomas Arzberger and Hans Kretzschmar†; VMVD and JQT were supported by Grants AG032953, AG017586 and AG010124; MG was supported by Grants AG032953, AG017586, AG010124 and NS044266; VMVD acknowledges EunRan Suh, PhD for assistance with sample handling and Elisabeth McCarty-Wood for help in selection of cases; JQT acknowledges Terry Schuck, John Robinson and Kevin Raible for assistance with neuropathological evaluation of cases. CVB and the Antwerp site were in part funded by the MetLife Foundation for Medical Research Award (to CVB), the Belgian Science Policy Office (BELSPO) Interuniversity Attraction Poles program; the Alzheimer Research Foundation (SAO-FRA); the Medical Foundation Queen Elisabeth (GSKE); the Flemish Government initiated Methusalem Excellence Program (to CVB); the Research Foundation Flanders (FWO) and the University of Antwerp Research Fund.. CVB, MC and JvdZ acknowledge the neurologists S Engelborghs, PP De Deyn, A Sieben, R Vandenberghe and the neuropathologist JJ Martin for the clinical and pathological diagnoses. CVB, MC and JvdZ further thank the personnel of the Genetic Service Facility of the VIB Department of Molecular Genetics (http://www.vibgeneticservicefacility.be) and the Antwerp Biobank of the Institute Born-Bunge for their expert support. IL and AB were supported by the program "Investissements d'avenir" ANR-10-IAIHU-06 and acknowledges the contribution of The French research network on FTLD/FTLD-ALS for the contribution in samples collection. BN is founded by Fondazione Cassa di Risparmio di Pistoia e Pescia (grant 2014.0365), SS is founded by the Cassa di Risparmio di Firenze (grant 2014.0310) and a grant from Ministry of Health n° RF-2010-2319722. JEN was supported by the Novo Nordisk Foundation, Denmark. MR was supported by the

German National Genome Network (NGFN); German Ministry for Education and Research Grant Number 01GS0465. JDR, MNR, NCF and JDW were supported by an MRC programme grant and the Dementia Platform UK, the NIHR Queen Square Dementia Biomedical Research Unit (BRU) and the Leonard Wolfson Experimental Neurology Centre. MGS was supported by MRC grant n G0301152, Cambridge Biomedical Research Centre and acknowledges Mrs K Westmore for extracting DNA. HM was supported by the Motor Neuron Disease Association (Grant 6057). RR was supported by P50 AG016574, R01 NS080882, R01 NS065782, P50 NS72187 and the Consortium for Frontotemporal Dementia; DWD was supported by P50NS072187, P50AG016574, State of Florida Alzheimer Disease Initiative, & CurePSP, Inc.; NRGR, JEP, RCP, DK, BFB were supported by P50 AG016574; KAJ was supported by R01 AG037491; WWS was supported by NIH AG023501, AG019724, Consortium for Frontotemporal Dementia Research; BLM was supported by P50AG023501, P01AG019724, Consortium for FTD Research; HR was supported by AG032306. JCvS was supported by Stichting Dioraphte Foundation (11 02 03 00), Nuts Ohra Foundation (0801-69), Hersenstichting Nederland (BG 2010-02) and Alzheimer Nederland. CG and HHC acknowledge families, patients, clinicians including Dr Inger Nennesmo and Dr Vesna Jelic, Professor Laura Fratiglioni for control samples and Jenny Björkström, Håkan Thonberg, Charlotte Forsell, Anna-Karin Lindström and Lena Lilius for sample handling. CG was supported by Swedish Brain Power (SBP), the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro), the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, Swedish Alzheimer Foundation, Swedish Research Council, Karolinska Institutet PhD-student funding, King Gustaf V and Queen Victoria's Free Mason Foundation. FP, AR, VD and FL acknowledge Labex DISTALZ. RF acknowledges the help and support of Mrs. June Howard at the Texas Tech University Health Sciences Center Office of Sponsored Programs for tremendous help in managing Material Transfer Agreement at TTUHSC.

GOBS: The GOBS study (PI DG and JB) was supported by the National Institute of Mental Health Grants MH0708143 (Principal Investigator [PI]: DCG), MH078111 (PI: JB), and MH083824 (PI: DCG & JB).

GSP: Brain Genomics Superstruct Project (GSP): Data were provided [in part] by the Brain GSP of Harvard University and the Massachusetts General Hospital, with support from the Center for BrainScience Neuroinformatics Research Group, the Athinoula A. Martinos Center for Biomedical Imaging and the Center for Human Genetic Research. Twenty individual investigators at Harvard and Massachusetts General Hospital generously contributed data to GSP. This work was made possible by the resources provided through Shared Instrumentation Grants 1S10RR023043 and 1S10RR023401 and was supported by funding from the Simons Foundation (RLB), the Howard Hughes Medical Institute (RLB), NIMH grants R01-MH079799 (JWS), K24MH094614 (JWS), K01MH099232 (AJH), and the Massachusetts General Hospital-University of Southern California Human Connectome Project (U54MH091665).

HUBIN: This work was supported by the Swedish Research Council (2006-2992, 2006-986, K2007-62X-15077-04-1, K2008-62P-20597-01-3, 2008-2167, 2008-7573, K2010-62X-15078-07-2, K2012-61X-15078-09-3, 14266-01A,02-03, 2017-949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation, and the HUBIN project.

HUNT: The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Movement Sciences, NTNU – Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI.

IMAGEN: This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) (PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (MR/N027558/1), the FP7 projects IMAGEMEND (602450; IMAging GEnetics for MENtal Disorders) and MATRICS (603016), the Innovative Medicine Initiative Project EU-AIMS (115300-2), the Medical Research Foundation and Medical Research Council grant MR/R00465X/1; the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the Swedish Research Council FORMAS, the Medical Research Council, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; eMED SysAlc01ZX1311A; Forschungsnetz AERIAL), the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-1, SM 80/7-2, SFB 940/1). Further support was provided by grants from: ANR (project AF12-NEUR0008-01 – WM2NA, and ANR-12-SAMA-

0004), the Fondation de France, the Fondation pour la Recherche Médicale, the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Fondation pour la Recherche Médicale (DPA20140629802), the Fondation de l'Avenir, Paris Sud University IDEX 2012; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1), and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence.

IMH: We thank the participants, their carers and research support staff of this study. This work was supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C-009/2006) research grants awarded to KS.

IMpACT: The International Multi-centre persistent ADHD CollaboraTion (IMpACT), is a consortium of clinical and basic researchers from several European countries (The Netherlands, Germany, Spain, Norway, The United Kingdom, Sweden), from the United States of America, and from Brazil. In the current study, the samples from the Netherlands node of IMpACT were used. This work was carried out on the Dutch national e-infrastructure with the support of SURF Cooperative. This works was supported by the Netherlands Organization for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NWO), i.e., the NWO Brain & Cognition Excellence Program (grant 433-09-229) and the Vici Innovation Program (grant 016-130-669 to BF). Additional support was received from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreements n◦ 602805 (Aggressotype), n◦ 602450 (IMAGEMEND), and n◦ 278948 (TACTICS) as well as from the European Community's Horizon 2020 Programme (H2020/2014–2020) under grant agreements n◦ 643051 (MiND), n◦ 667302 (CoCA), and n◦ 728018 (Eat2beNICE). The work was also supported by grants for the ENIGMA Consortium (Foundation for the National Institutes of Health (NIH); grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership.

LBC1936: We thank the participants and research support staff of this study. The work was undertaken as part of the Cross Council and University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE; http://www.ccace.ed.ac.uk). This work was supported by a Research into Ageing programme grant (to I.J.D.) and the Age UK-funded Disconnected Mind project (http://www.disconnectedmind.ed.ac.uk; to I.J.D. and J.M.W.), with additional funding from the UK Medical Research Council (MRC Mr/M01311/1, G1001245/96077, G0701120/79365 to I.J.D., J.M.W. and M.E.B.). The whole genome association part of this study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC; Ref. BB/F019394/1). J.M.W. is supported by the Scottish Funding Council through the SINAPSE Collaboration (http://www.sinapse.ac.uk). CCACE (MRC MR/K026992/1) is funded by the BBSRC and MRC. The image acquisition and analysis was performed at the Brain Research Imaging Centre, University of Edinburgh (http://www.bric.ed.ac.uk). MVH is supported by the Row Fogo Charitable Trust.

LIBD: This work was supported by direct funding from the NIMH intramural research program of the NIH to the Weinberger Lab and by support from the LIeber Institute for Brain Development and the Maltz Research Laboratories.

MCIC: The authors wish to thank our many colleagues who served as mentors, advisors and supporters during the inception and conduct of the study including Donald Goff, Gina Kuperberg, Jill Goldstein, Martha Shenton, Robert McCarley, Stephan Heckers, Cynthia Wible, Raquelle Mesholam-Gately, and Mark Vangel. We thank the study staff and clinicians at each site that were responsible for the data acquisition. These include: Stuart Wallace, Ann Cousins, Raquelle Mesholam-Gately, Steven Stufflebeam, Oliver Freudenreich, Daphne Holt, Laura Kunkel, Frank Fleming, George He, Hans Johnson, Ron Pierson, Arvind Caprihan, Phyllis Somers, Christine Portal, Kaila Norman, Diana South, Michael Doty and Haley Milner. We would also like to acknowledge the expert guidance on image and other types of data acquisition we obtained from Lee Friedman, Stephan Posse, Jorge Jovicich, and Tom Wassink. We would also like to acknowledge the many research assistants, students and colleagues who assisted in data curation over the years since data acquisition was completed. These include: Stuart Wallace, Carolyn Zyloney, Komal Sawlani, Jill Fries, Adam Scott, Dylan Wood, Runtang Wang, William Courtney, Angie Guimaraes, Lisa Shenkman, Mustafa Kendi, Aysa Tuba Karagulle Kendi, Ryan Muetzel, Tara Biehl, and Marcus Schmidt. This work was supported primarily by the Department of Energy DE-FG02-99ER62764 through its support of the Mind Research Network (MRN, formerly known as the MIND Institute) and the consortium as well as by the National Association for Research in Schizophrenia and Affective Disorders (NARSAD) Young Investigator Award (to SE) as well as through the Blowitz-Ridgeway and Essel Foundations and a ZonMw TOP 91211021 (to TW), the DFG research fellowship (to SE), the Mind Research Network, National Institutes of Health through NCRR 5MO1-RR001066 (MGH General Clinical Research Center), NIMH K08 MH068540, the Biomedical Informatics Research Network with NCRR Supplements to P41 RR14075 (MGH), M01 RR 01066 (MGH), NIBIB

R01EB006841 (MRN), R01EB005846 (MRN), 2R01 EB000840 (MRN), 1RC1MH089257 (MRN), as well as grant U24 RR021992.

Meth-CT: This study was supported by the Medical Research Council, South Africa.

MIRECC: We thank the US military veterans who participated in this research. The Study was supported by National Institute of Mental Health (1R01MH111671) and the US Department of Veterans Affairs (VISN6 MIRECC).

MooDS: This work was supported by the German Ministry for Education and Research (BMBF) grants (BMBF National Genome Research Network: NGFN-Plus MooDS "Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia"; see under http://www.ngfn.de/en/schizophrenie.html; e:Med Programme: Integrated Network IntegraMent, Integrated Understanding of Causes and Mechanisms in Mental Disorders, grant 01ZX1314A to MMN, grant 01ZX1614A to FD and MMN), and supported by grants from the German Research Foundation the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, FOR 1617 as well as Excellence Cluster Exc 257).

MPIP: The MPIP Munich Morphometry Sample comprises images acquired as part of the Munich Antidepressant Response Signature (MARS) Study and the Recurrent Unipolar Depression (RUD) Case-Control study performed at the MPIP, and control subjects acquired at the Ludwig-Maximilians-University, Munich, Department of Psychiatry. We would like to acknowledge all patients and control subjects who have participated in these studies. We are grateful to Rosa Schirmer, Elke Schreiter, Reinhold Borschke, Ines Eidner and Anna Olynyik for supporting MR acquisition and data management. We thank the staff of the Center of Applied Genotyping for generating the genotypes of the MARS cohort. We further thank Dorothee P. Auer for initiating the RUD-MR substudy and Elisabeth Binder for supporting participation in ENIGMA. We are grateful to GlaxoSmithKline for providing the genotypes of the Recurrent Unipolar Depression Case-Control Sample. The study was supported by a grant of the Exzellenz-Stiftung of the Max Planck Society. This work has also been funded by the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), FKZ 01GS0481.

MPRC: Support was received from NIH grants U01MH108148, 2R01EB015611, R01DA027680, R01MH085646, P50MH103222, U54 EB020403, and T32MH067533, NSF grants IIS-1302755 and MRI-1531491, a State of Maryland contract (M00B6400091), and a Pfizer research grant.

MÜNSTER: This work was funded by the German Research Foundation (SFB-TRR58, Projects C09 and Z02 to UD) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17 to UD).

NCNG: The study was supported by the Bergen Research Foundation (BFS), the University of Bergen, the Research Council of Norway (RCN) (including FUGE grant nos. 151904 and 183327, Psykisk Helse grant no. 175345, RCN grants 154313/V50 to I.R. and 177458/V50 to T.E.), Helse Sørøst RHF to T.E. (grant 2012086), and Dr Einar Martens Fund.

NESDA: The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1002) and is supported by participating universities (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen) and mental health care organizations.Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002); the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL), VU University's Institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, University Medical Center Groningen, Leiden University Medical Center, National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health.Computing was supported by BiG Grid, the Dutch e-Science Grid, which is financially supported by NWO.

NeuroIMAGE: The NeuroIMAGE study was supported by NIH Grant R01MH62873(to Stephen V. Faraone), NWO Large Investment Grant 1750102007010(to Jan Buitelaar), ZonMW grant 60-60600-97-193, NWO grants 056-13-015 and 433-09-242, and matching grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and Vrije Universiteit Amsterdam. Further support was received from the European Union FP7 programmes TACTICS (grant agreement 278948), IMAGEMEND

(grant agreement 602450), Aggressotype (grant agreement 602805), CoCA (grant agreement 667302), and Eat2beNICE (grant agreement 728018).

NTR: Netherlands Twin Register: Funding was obtained from the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-002, 912-10-020, 904-61-193,480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-Groot 480-15-001/674, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI –NL, 184.021.007 an 184.033.111); Spinozapremie (NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (URF) to DIB; Amsterdam Public Health research institute (former EMGO+) , Neuroscience Amsterdam research institute (former NCA) ; the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community's Seventh Framework Program (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Advanced, 230374, ERC Starting grant 284167), Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the National Institutes of Health (NIH, R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by NWO through grant 2018/EW/00408559, BiG Grid, the Dutch e-Science Grid and SURFSARA.

OATS: We would like to thank the participants and their supporters for their time and generosity. We acknowledge and thank the contributions of the OATS research team. OATS is supported by the Australian National Health and Medical Research Council (NHMRC)/Australian Research Council Strategic Award (Grant 401162) and the NHMRC Project grant 1405325. This study was facilitated through Twins Research Australia, a national resource in part supported by a Centre for Research Excellence from the NHMRC. DNA was extracted by Genetic Repositories Australia (NHMRC Grant 401184). Genome-wide genotyping was performed by the Diamantina Institute, University of Queensland. A CSIRO Flagship Collaboration Fund Grant partly funded the genotyping.

OSAKA: This research was supported by AMED under Grant Number JP18dm0307002, JP18dm0207006 (Brain/MINDS) and JSPS KAKENHI Grant Number J16H05375.

PAFIP: The authors wish to thank all PAFIP research team and all patients and family members who participated in the study. We wish to acknowledge IDIVAL Neuroimaging Unit for imaging acquirement and analysis. We thank Valdecilla Biobank for its help in the technical execution of this work. This work was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918), MINECO (SAF2010-20840-C02-02 and SAF2013-46292-R) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study.

PDNZ: We thank the patients who participated in this study, staff at the New Zealand Brain Research Institute and Pacific Radiology Christchurch for study co-ordination and image acquisition, and Ms Allison Miller for DNA preparation and banking. Neurological Foundation of New Zealand; Canterbury Medical Research Foundation; University of Otago Research Grant; Jim and Mary Carney Charitable Trust (Whangarei, New Zealand).

PING: PING was supported by the National Institute on Drug Abuse (RC2DA029475) and the National Institute of Child Health and Human Development (R01HD061414) in the U.S.

PPMI: Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. Parkinson's Progression Markers Initiative, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Allegran, Avid Radiopharmaceuticals, Biogen Idec, BioLegend, Bristol-Meyers Squibb, Denali Therapeutics, GE Healthcare, Genentech, GSK-GlaxoSmithKline, Eli Lilly & Co., F. Hoffman-La Roche Ltd., Lundbeck Pharmaceuticals, Merck and Company, MSD-Meso Scale Discovery, Pfizer, Piramal, Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, TEVA Pharmaceutical Industries, UCB Pharma SA, and Golub Capital (http://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors/). Support for the image and genetic data analysis of PPMI was provided in part by MJFF grant number 14848 (to N.J.)

QTIM: We thank the twins and singleton siblings who gave generously of their time to participate in the QTIM study. We also thank the many research assistants, radiographers, and IT support staff for data acquisition

and DNA sample preparation. National Institute of Child Health & Human Development (R01 HD050735); National Institute of Biomedical Imaging and Bioengineering (Award 1U54EB020403-01, Subaward 56929223); National Health and Medical Research Council (Project Grants 496682, 1009064 and Medical Bioinformatics Genomics Proteomics Program 389891).

SHIP and SHIP/TREND: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Whole-body MR imaging was supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. The SHIP authors are grateful to Mario Stanke for the opportunity to use his Server Cluster for the SNP imputation as well as to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-Trend cohort.

Sydney MAS: We would like to thank and acknowledge the generosity of our participants and their supporters in contributing to this study. We would also like to thank the Sydney MAS Research Team. Sydney MAS is supported by the National Health and Medical Research Council (NHMRC)/Australian Research Council Strategic Award (Grant 401162) and NHMRC Program Grants (350833, 568969). DNA was extracted by Genetic Repositories Australia (NHMRC Grant 401184). Genome-wide genotyping was performed by the Ramaciotti Centre, University of New South Wales.

SYS: The SYS has been funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Computations were performed on the GPC supercomputer at the SciNet HPC Consortium. SciNet is funded by: the Canada Foundation for Innovation under the auspices of Compute Canada; the Government of Ontario; Ontario Research Fund - Research Excellence; and the University of Toronto.

TCD-NUIG: Included data from two sites. *NUI Galway:* data collection was supported by the Health Research Board (HRA_POR/2011/100). *Trinity College Dublin:* this research was supported by The Science Foundation Ireland Research Investigator project, awarded to Gary Donohoe (SFI: 12.IP.1359).

TOP and TOP3T: are part of TOP, which is supported by the Research Council of Norway (223273, 213837, 249711, 226971, 262656), the South East Norway Health Authority (2017-112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ-MED-008) and the European Community's Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND).

UiO2016 and UiO2017: are part of TOP and STROKEMRI, which is supported by the Norwegian ExtraFoundation for Health and Rehabilitation (2015/FO5146), the Research Council of Norway (249795, 248238), and the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073).

UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number '11559'.

UMCU: The UMCU cohort consists of several independent studies, which were supported by The Netherlands Organisation for Health Research and Development (ZonMw) TOP 40-008-12-98-13009, Geestkracht programme of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1001), the Stanley Medical Research Institute (Dr. Nolen), the Brain and Behavior Research Foundation (2013-2015 NARSAD Independent Investigator grant number 20244 to M.H.J.H.), The Netherlands Organisation for Scientific Research (2012-2017 VIDI grant number 452-11-014 to N.E.M.H.), The Netherlands Organisation for Health Research and Development (ZonMw grant number 908-02-123 to H.E.H.), The Netherlands Organisation for Scientific Research (VIDI grant number 917-46-370 to H.E.H.).

UNICAMP: Supported by FAPESP (São Paulo Research Foundation) grant #2013/07559-3: The Brazilian Institute of Neuroscience and Neurotechnology (BRAINN).

Author Contributions (in alphabetical order)
K.L.G. and N.J. contributed to this work as co-first authors (*). J.N.P., L.C.-C., J.B., D.P.H., P.A.L., F.P. contributed to this work as co-second authors. J.L.S., P.M.T., S.E.M. contributed to this work as co-last authors (**).

Central Analysis and Coordination Group
C.R.K.C., D.P.H., F.P., J.Br., J.L.S., J.N.P., K.L.G., L.C.-C., L.Z., M.A.B.M., N.J., N.S., P.A.L., P.M.T., S.E.M.

Manuscript Writing and Preparation
D.P.H., J.Br., J.L.S., J.N.P., K.L.G., L.C.-C., N.J., P.A.L., P.M.T., S.E.M.

Project Support
D.Ga., M.A.B.M., M.J., N.S., R.E., V.R., Y.G.

Cohort Principal Investigator
A.A.V., A.C., A.H., A.J.F., A.J.H., A.K.H., A.M.D., A.M.-L., A.R.H., A.W.T., B.C.-F., B.S.P., B.T.B., B.W., B.W.J.H.P., C.A.H., C.Dep., C.F., C.M., D.Am., D.C.G., D.I.B., D.J.S., D.P., D.R.W., D.v.E., E.G.J., E.J.C.d.G., E.L.H., F.C., G.D., G.F., G.G.B., G.L.C., G.S., H.B., H.E.H.P., H.F., H.G.B., H.J.G., H.V., H.W., I.A., I.E.Som., I.J.D., I.M., J.B.J.K., J.Bl., J.C.D.-A., J.K.B., J.-L.M., J.L.R., J.N.T., J.O., J.R.B., J.W.S., J.Z., K.L.M., K.S., L.M.R., L.N., L.R., L.T.W., M.E.B., M.H.J.H., M.J.W., M.K.M.A., M.R., N.D., N.J., N.J.A.v.d.W., O.A.A., O.G., P.G.S., P.J.H., P.K., P.M.T., P.S.S., R.A.M., R.A.O., R.H., R.L.B., R.L.G., R.S.K., S.Ca., S.Des., S.E.F., S.L.H., S.M.S., S.R., T.E., T.J.A., T.J.C.P., T.L.J., T.P., T.T.J.K., U.D., V.C., W.C., W.U.H., X.C., Z.P.

Imaging Data Collection
A.B., A.d.B., A.F.M., A.J., A.J.H., A.K., A.K.H., A.L.G., A.M.D., A.N.H., A.P., A.R.H., A.R.K., A.U., B.A.M., B.-C.H., B.D., B.Pi., B.W., B.W.J.H.P., C.B., C.D.W., C.J., C.L.B., C.L.Y., C.M., C.R.J., C.S.Re., D.Am., D.C.G., D.Gr., D.H.M., D.J., D.J.H., D.J.V., D.M.C., D.P.O., D.R.W., D.S.O., D.T.-G., D.v.E., D.v.R., D.Z., E.A., E.B.Q., E.J.C.d.G., E.L.H., E.Sh., G.B.P., G.D., G.F., G.I.d.Z., G.L.C., G.R., G.S., H.V., H.Y., I.A., I.E.Som., J.A.T., J.E.C., J.E.N., J.K.B., J.-L.M., J.-L.M., J.L.R., J.M.F., J.M.W., J.N.T., J.R., J.T.V., K.D., K.K., K.L.M., K.O.L., K.S., L.M.R., L.R., L.T.W., M.B.H., M.E.B., M.Fu., M.H.J.H., M.Ho., M.-J.v.T., M.J.W., M.-L.P.M., N.E.M.v.H., N.H., N.J.A.v.d.W., N.K.H., N.O., O.G., P.A.G., P.G.S., P.K., P.N., P.S.S., R.A.O., R.B., R.H., R.L.B., R.L.G., R.R., R.S.K., R.W., S.A., S.C.M., S.Ca., S.Er., S.Ko., S.M., S.M.S., T.G.M.v.E., T.R.M., T.Wh., T.W.M., U.D., V.C., V.S.M., W.D.H., W.H., W.W., X.C.

Imaging Data Analysis
A.F.M., A.H.Z., A.J.H., A.J.S., A.L.G., A.M.D., A.R., A.R.K., A.S., A.Th., A.U., B.A.G., B.C.R., B.K., B.S.P., C.B., C.C.F., C.C.H., C.D.W., C.J., C.L.Y., C.R.K.C., C.S.Ro., D.Al., D.C.G., D.Gr., D.H., D.J., D.J.H., D.M.C., D.P.H., D.P.O., D.T.-G., D.v.d.M., D.v.E., D.v.R., D.Z., E.E.L.B., E.Sh., E.Sp., E.W., F.M.R., F.P., F.S., G.I.d.Z., G.R., H.J.G., I.A., I.E.Som., I.K.A., J.A.T., J.B.J.K., J.C.V.M., J.-L.M., J.L.R., J.L.S., J.M.W., J.R., J.Z., K.D., K.L.M., K.N., K.S., K.W., L.B.L., L.H., L.Sa., L.Sc., L.Sh., L.T.S., L.T.W., L.v.E., L.Z., M.A., M.A.H., M.B.H., M.C., M.E.B., M.Fu., M.Ho., M.-J.v.T., M.J.W., M.Ki., M.P.Z., N.E.M.v.H., N.J., N.O., N.T.D., O.G., P.G.S., P.K., P.M.T., P.N., R.B., R.K., R.L.G., R.M.B., R.R., R.R.-S., S.A., S.Ca., S.Des., S.Eh., S.Er., S.F.F., S.I.T., S.Ka., S.Ke., S.L.R., S.M.C.d.Z., S.R.M., T.A., T.A.L., T.G., T.G.M.v.E., T.J., T.K., T.L.P., T.P.G., T.R.M., T.Wh., T.Wo., T.W.M., U.D., W.W., X.C., Z.Z.

Genetic Data collection
A.A.A., A.A.-K., A.d.B., A.J.F., A.J.H., A.J.S., A.K.H., A.M.D., A.P., A.R.H., A.R.K., B.-C.H., B.T.B., B.W., B.W.J.H.P., C.B., C.D.W., C.F., C.M., C.P.D., C.S.Re., D.C.G., D.H.M., D.R.W., D.W.M., D.Z., E.A., E.B.Q., E.G.J., E.J.C.d.G., E.L.H., F.D., F.M., F.R.T., G.D., G.E.D., G.F., G.H., G.L.C., G.S., H.V., H.Y., I.E.Som., I.L.-C., J.A.T., J.B.J.K., J.Bl., J.E.C., J.E.N., J.-J.H., J.J.L., J.K.B., J.-L.M., J.-L.M., J.L.R., J.M.F., J.R., J.W.S., K.A.M., K.D., K.O.L., K.S., L.M.R., L.R., L.Sh., M.A.K., M.H.J.H., M.Ha., M.Ho., M.J.W., M.-L.P.M., M.M.N., M.N., N.E.M.v.H., N.G.M., N.J.A.v.d.W., N.K.H., N.O., O.G., P.K., P.R.S., P.S.S., R.A.O., R.C.G., R.H., R.L.B., R.R., R.Se., R.S.K., R.W., S.A., S.Ci., S.Dj., S.E.F., S.Eh., S.Er., S.L.H., S.M.S., T.G.M.v.E., T.J.A., T.K.d.A., T.L.P., T.W.M., U.D., V.C., V.M.S., X.C.

Genetic Data Analysis
A.A.-K., A.J.F., A.J.H., A.J.S., A.M.D., A.R.K., A.Te., A.Th., B.C.-D., B.K., B.M.-M., B.Pü., B.S.P., B.T.B., C.C.F., C.D.W., C.L.V., C.S.Re., C.S.Ro., C.W., C.Y.S., D.C.G., D.K., D.P.H., D.v.d.M., D.v.E., E.G.J., E.L.H., E.V., E.W., F.M., H.-R.E., I.E.J., I.E.Som., I.E.Søn., I.L.-C., I.O.F., J.Bl., J.Br., J.F.P., J.H.V., J.-J.H., J.L.R., J.L.S., J.N.P., J.S., J.W.C., J.W.S., K.E.T., K.L.G., K.N., L.C.-C., L.M.O.L., L.Sh., L.Z., M.A.A.A., M.B., M.E.G., M.Fu., M.Ha., M.I., M.J., M.J.W., M.Ki., M.Kl., M.Kn., M.L., M.M.J.v.D., N.A.G., N.G.M., N.J., N.J.A., N.K.H., N.M.-S., N.R.M., O.G., P.A.L., P.G.S., P.H.L., P.K., P.M.T., P.R.S., Q.C., R.A.O., R.M.B., R.R., R.Se., S.Da.,

S.Des., S.E.M., S.Eh., S.G., S.H.W., S.L.H., S.M.C.d.Z., S.N., S.R.M., T.A.L., T.G., T.G.M.v.E., T.J., T.K.d.A., T.M.L., Y.M., Y.W.

CHARGE Study Design
B.M., C.Dec., C.L.S., E.H., G.V.R., H.H.H.A., H.J.G., J.C.B., L.J.L., M.A.I., M.Fo., O.L.L., Q.Y., R.Sc., S.Deb., S.S., T.H.M., V.G., W.T.L.


a
0 Global (SA:8; TH:1)
1 Frontal Pole (SA:1; TH:0)
2 Medial Orbitofrontal (SA:1; TH:0)
3 Lateral Orbitofrontal (SA:3; TH:0)
4 Rostral Anterior Cingulate (SA:0; TH:0)
5 Caudal Anterior Cingulate (SA:2; TH:0)
6 Superior Frontal (SA:1; TH:0)
7 Rostral Middle Frontal (SA:4; TH:0)
8 Pars Orbitalis (SA:4; TH:0)
9 Pars Triangularis (SA:4; TH:0)
10 Pars Opercularis (SA:2; TH:0)
11 Caudal Middle Frontal (SA:3; TH:0)
12 Paracentral (SA:0; TH:0)
13 Precentral (SA:6; TH:0)
14 Postcentral (SA:6; TH:2)
15 Precuneus (SA:5; TH:0)
16 Superior Parietal (SA:10; TH:1)
17 Supramarginal (SA:7; TH:0)
18 Inferior Parietal (SA:9; TH:0)
19 Posterior Cingulate (SA:4; TH:0)
20 Isthmus Cingulate (SA:2; TH:0)
21 Insula (SA:4; TH:0)
22 Entorhinal (SA:1; TH:0)
23 Parahippocampal (SA:2; TH:1)
24 Fusiform (SA:4; TH:0)
25 Temporal Pole (SA:0; TH:0)
26 Inferior Temporal (SA:0; TH:0)
27 Middle Temporal (SA:3; TH:1)
28 Superior Temporal (SA:3; TH:0)
29 Banks of the Superior Temporal Sulcus (SA:2; TH:1)
30 Transverse Temporal (SA:3; TH:1)
31 Lingual (SA:12; TH:0)
32 Pericalcarine (SA:14; TH:1)
33 Cuneus (SA:4; TH:1)
34 Lateral Occipital (SA:6; TH:0)
b
Surface Area P < 8.3e-10
Surface Area P < 5e-8
Thickness P < 8.3e-10
Thickness P < 5e-8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
0
6
12
18
Number of independent loci
c


a
ICV
ICV | Height
Height
Global SA (this paper)
Hippocampus | ICV (adjusted p = 0.051)
Putamen | ICV
Caudate | ICV
Accumbens | ICV
Palladium | ICV
Thalamus | ICV
-0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
b
H1
H9
Female brain
Male brain
Cingulate gyrus
Dorsolateral prefrontal
Inferior temporal lobe
Angular gyrus
Hippocampus (middle)
Substantia nigra
Anterior caudate
H1-derived neuronal progenitor
H9-derived neuronal progenitor
H9-derived neuron
Fetal Stomach
Foreskin fibroblast primary cells
Pancreas
Germinal Zone
Cortical Plate
Surface Area
Thickness
Enrichment
ESC
Fetal brain
Adult brain
In vitro neural cultures
Non-neural tissue
Fetal cortical wall
c
-log10(p)
rs62057153
rs4273712
rs10878349
rs34464850
rs1628768
rs2802295
rs190958130
rs12630663
rs7715167
rs11171739
rs11012732
rs2980497
rs7824177
rs6738528
rs11692435
rs13110077
rs630934
rs17769552
d
Total Surface Area
-log10 P-value
rs1628768
r2
WBP1L
AS3MT
CNNM2
RPEL1
INA
TAF5
PFN1P11
RP11-72N1.1
NT5C2
PCGF6
USMG5
RNU6-1231P
RP11-753C18.8
AL360001.1
RNU11-3P
MIR1307
CYP17A1
C10orf32
RP11-332019.2
ST13P13
PDCD11
15-core Chromatin State
TssA
TxFlnk
Tx/Wk
Enh
Het
BivFlnk
ReprPC
Quies
TssAFlnk
Tx
EnhG
ZNF/Rpts
TssBiv
EnhBiv
ReprPCWk
Adult cortex
Fetal brain
Astrocytes
Chr10 104.60
104.80
105.00 Mb
Brainspan Tissue
DFC
MFC
M1C
PCx
IPC
TCx
ITC
V1C
VFC
OFC
M1C-S1C
S1C
A1C
STC
Ocx
Prenatal:Early
Mid
Late
Infancy
Childhood
Adolescence
Adulthood
Sample
Tissue
NT5C2
INA
WBPL1
C10orf32
AS3MT
Gene expression (log2 RPKM): Low
High
f
Average Thickness
-log10 P-value
rs630934
r2
RSPA
AC099332.1
MOBP
SNORA6
SNORA62
Chr3 39.46
39.48
39.50
39.52
39.54 Mb
RPSA
MOBP
e
g
-15
-10
-5
0
5
10
15
Zscore


a
FRONTAL
PARIETAL
TEMPORAL
OCCIPITAL
% h²
Correlation
-1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1
b
FRONTAL
PARIETAL
TEMPORAL
OCCIPITAL
% h²
Correlation
-1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1
c
regulation of organelle organization
regulation of translation
chromatin modification
PcG protein complex
methyltransferase complex
histone methyltransferase complex
chromatin binding
histone deacetylase binding
nuclear chromosome part
covalent chromatin modification
protein kinase binding
nuclear chromosome
chromatin remodeling complex
histone modification
kinase binding
0 1 2 3 4 5 6
-log10(P-value)
d
Wnt receptor signaling pathway
regulation of anatomical structure morphogenesis
canonical Wnt receptor signaling pathway
negative regulation of Wnt receptor signaling pathway
vasculature development
blood vessel development
regulation of Wnt receptor signaling pathway
pattern specification process
regulation of canonical Wnt receptor signaling pathway
regionalization
blood vessel morphogenesis
negative regulation of canonical Wnt receptor signaling pathway
tube morphogenesis
head development
embryo development ending in birth or egg hatching
0 1 2 3 4 5 6
-log10(P-value)


a
Mean Precentral SA
-log10 P-value
rs1080066
rs4924346
rs11639391
rs2033939
rs4924345
r2
←RP11-624L4.1
RP11-624L4.2 →
←RP11-27M9.1
THBS1→
Neural progenitor cells chromatin interactions
15-core Chromatin State
TssA TxFlnk Tx/Wk Enh Het BivFlnk ReprPC Quies
TssAFlnk Tx EnhG ZNF/Rpts TssBiv EnhBiv ReprPCWk
Adult cortex
Fetal brain
Astrocytes
Chr15 39.65 39.70 39.75 39.80 39.85 Mb
Brainspan Tissue
DFC MFC M1C PCx IPC TCx ITC V1C
VFC OFC M1C-S1C S1C A1C STC Ocx
Prenatal:Early Mid Late Infancy Childhood Adolescence Adulthood
Sample
Tissue
THBS1
Gene expression (log2 RPKM): Low High
b
-15 -10 -5 0 5 10 15
Zscore
c
15q14
+ Precentral SA (rs17601140) 1.20e-15
– Superior Temporal SA (rs115241741) 2.70e-12
– Supramarginal SA (rs62007727) 6.84e-11
– Supramarginal SA (rs78502100) 5.59e-15
+ Precentral SA (rs11070172) 5.09e-14
– Transverse Temporal SA (rs4923822) 1.59e-08
– Precentral SA (rs3862145) 4.53e-13
– Rostral Middle Frontal SA (rs1080066) 1.81e-11
– Postcentral SA (rs3862145) 7.17e-10
– Pars Triangularis SA (rs4924345) 1.64e-14
+ Precentral SA (rs1080066) 4.41e-188
– Pars Opercularis SA (rs2033939) 4.22e-24
+ Postcentral TH (rs11639391) 1.29e-86
– Superior Parietal SA (rs4924345) 1.85e-38
– Supramarginal SA (rs4924345) 4.04e-54
+ Postcentral SA (rs4924346) 1.50e-77
d
Human: rs1080066
P = 7.9e-21
P = 1
Chimpanzee
Orangutan
Gorilla
Sulci depth (mm)
Location within sulci (superior to inferior)
e
Mean Pericalcarine SA
-log10 P-value
rs73313052
rs74826997
rs78580207
rs2164950
rs117461235
r2
DACT1→
←AL121819.1
RP11-112J1.2→
DAAM1→
RP11-112J1.1→
←CTD-2315A10.2
←RP11-112J1.3
CTD-2315A10.1→
15-core Chromatin State
Adult cortex
Fetal brain
Astrocytes
Chr14 59.20 59.40 59.60 59.80 Mb
Brainspan Tissue
Prenatal:Early Mid Late Infancy Childhood Adolescence Adulthood
Sample
Tissue
DAAM1
DACT1
Gene expression (log2 RPKM): Low High
f
-15 -10 -5 0 5 10 15
Zscore
g
14q23.1
+ Middle Temporal TH (rs160459) 3.85e-17
– Fusiform SA (rs17834032) 3.12e-12
+ Banks of the Superior Temporal SA (rs160458) 4.58e-15
– Entorhinal SA (rs7141150) 5.31e-13
+ Banks of the Superior Temporal TH (rs149142) 6.71e-15
– Pericalcarine TH (rs117461235) 3.20e-11
+ Supramarginal SA (rs221326) 1.78e-14
– Cuneus TH (rs78580207) 8.64e-16
– Cuneus SA (rs170239) 7.34e-10
+ Supramarginal SA (rs2164950) 1.03e-24
+ Precuneus SA (rs73313052) 2.51e-35
– Lingual SA (rs74826997) 1.16e-26
– Pericalcarine SA (rs73313052) 1.82e-34
– Cuneus SA (rs73313052) 3.40e-29
– Lateral Occipital SA (rs74826997) 9.60e-32
h
Mean Insular SA
-log10 P-value
rs6505147
r2
←SSH2
AC104996.1→
NSRP1→
ANKRD13B→
RP11-82O19.1→
snoU13→
EFCAB5→
MIR423→
←SLC6A4
←CORO6
←RPL21P123
SNORA70→
RPL9P30→
RP11-338L22.3→
←AC104984.4
RP11-354P11.4→
←RP11-68I3.10
RP11-68I3.5→
RP11-338L22.2→
RP11-1148O4.1→
←RP11-1148O4.2
←RNU6-920P
←RP11-82O19.2
←RNY4P13
←MIR3184
←RP11-68I3.11
←RP11-354P11.3
←RP11-354P11.8
15-core Chromatin State
Adult cortex
Fetal brain
Astrocytes
Chr17 28.0 28.1 28.2 28.3 28.4 28.5 Mb
Brainspan Tissue
Prenatal:Early Mid Late Infancy Childhood Adolescence Adulthood
Sample
Tissue
SSH2
CORO6
EFCAB5
Gene expression (log2 RPKM): Low High


a
Parkinson's disease
General cognitive function
Educational attainment
Anorexia nervosa
Bipolar disorder
Obsessive compulsive disorder
Autism
Epilepsy
Frontotemporal dementia
Subjective well-being
Irritable bowel disease
Anxiety
Cigarettes per day
Schizophrenia
Aggression
Antisocial behavior
Loneliness
Neuroticism
Major depressive disorder
Depressive symptoms
Alzheimer's disease
ADHD
PTSD
Insomnia
Genetic Correlation (r_G)
-.4
-.2
0
.2
.4
b
Parkinson's Disease
General cognitive function
Major Depressive Disorder
ADHD
Insomnia
-.3
-.2
-.1
0
.1
.2
.3
Genetic Correlation (r_G)